NBER WORKING PAPER SERIES

IS MEDICINE AN IVORY TOWER? INDUCED INNOVATION, TECHNOLOGICAL
OPPORTUNITY, AND FOR-PROFIT VS. NON-PROFIT INNOVATION
Jay Bhattacharya
Mikko Packalen
Working Paper 13862
http://www.nber.org/papers/w13862

NATIONAL BUREAU OF ECONOMIC RESEARCH
1050 Massachusetts Avenue
Cambridge, MA 02138
March 2008

We thank Raphael Godefrey, Neeraj Sood, and Darius Lakdawalla for helpful comments. Bhattacharya
thanks the National Institute on Aging for funding his work on this project. The views expressed herein
are those of the author(s) and do not necessarily reflect the views of the National Bureau of Economic
Research.
NBER working papers are circulated for discussion and comment purposes. They have not been peerreviewed or been subject to the review by the NBER Board of Directors that accompanies official
NBER publications.
© 2008 by Jay Bhattacharya and Mikko Packalen. All rights reserved. Short sections of text, not to
exceed two paragraphs, may be quoted without explicit permission provided that full credit, including
© notice, is given to the source.

Is Medicine an Ivory Tower? Induced Innovation, Technological Opportunity, and For-Profit
vs. Non-Profit Innovation
Jay Bhattacharya and Mikko Packalen
NBER Working Paper No. 13862
March 2008
JEL No. I1,L31,O33
ABSTRACT
This paper examines whether the composition of medical research responds to changes in disease incidence
and research opportunities. The paper also provides new evidence on induced pharmaceutical innovation.
In both cases we use the change in the demographic structure of the market (measured by age structure
and obesity prevalence) to test the induced innovation hypothesis. Technological opportunity is calculated
from estimates of structural productivity parameters. The extent of inventive activity is measured from
the MEDLINE database on 16 million biomedical publications. We match these data with data on
disease incidence. We show that medical research responds to changes in disease incidence and research
opportunities. We also find that pharmaceutical innovation responds to aging- and obesity-induced
changes in potential market size.

Jay Bhattacharya
117 Encina Commons
Center for Primary Care
and Outcomes Research
Stanford University
Stanford, CA 94305-6019
and NBER
jay@stanford.edu
Mikko Packalen
University of Waterloo
Department of Economics
200 University Avenue West
Waterloo, ON N2L 3G1
Canada
packalen@uwaterloo.ca

1

Introduction

One key virtue of for-pro…t allocation is that decisions made by for-pro…t …rms must necessarily respond to changes in the market. That is, for-pro…t producers must shape their
products to …t the demands of their consumers or clients, or else risk failure. There is
abundant evidence that for-pro…t producers (for instance in the pharmaceutical industry)
innovate according to market demand (see Acemoglu and Linn, 2004).
Non-pro…t allocation, on the other hand, imposes looser budget constraints on …rms
(Lakdawalla and Philipson, 2006). In principle at least, loose constraints could insulate
non-pro…t producers from the raw demand of the market, and hence divorce production
decisions from demand. This sort of reasoning has often been applied to academic publishing,
and is a good working de…nition of an academic ivory tower. While there may be good
reasons to insulate some markets with non-pro…t production from the vagaries of the market,
academic medicine is not such a market. Despite the evident importance that the non-pro…t
producers of academic medicine respond to the market (that is, the epidemiology of patient
health), there is little extant evidence that they do. In fact, to our knowledge there is little
extant evidence on whether non-pro…t allocation induces a link between market demand and
innovation in any market.
We show that the direction of medical research does respond to changes in the expected
number of people who bene…t from the research and changes in technological opportunity.
The identi…cation of the technological opportunity e¤ect relies on our analysis of a formal
model of optimal allocation of research e¤ort. The analysis enables us to estimate the structural productivity parameters that govern technological opportunity. The disease incidence
e¤ect is identi…ed using aging- and obesity-driven exogenous variation in disease incidence.
To our knowledge our study is the …rst study on non-pro…t innovation that identi…es the technological opportunity e¤ect and the …rst study on non-pro…t innovation that uses exogenous
variation to identify the induced innovation e¤ect. We also present evidence on aging- and
1

obesity-induced pharmaceutical innovation. While the …nding of aging-induced pharmaceutical innovation replicates a …nding in the existing literature the …nding of obesity-induced
pharmaceutical innovation is new.
The empirical analysis is facilitated by the construction of a match between a medical
vocabulary and data on disease incidence. This match enables us to use the massive indexed
MEDLINE database on 16 million biomedical publications to measure innovation in medicine. To our knowledge our study is the …rst to take advantage of the panel nature of this
database which is rich in its information content and thereby has great potential for future
innovation research.

2

Background

The literature on the determinants of non-pro…t innovation is near non-existent. Lichtenberg
(1999) and Lichtenberg (2006) are exceptions. Lichtenberg (1999) …nds a positive correlation
between public biomedical funding and both the disease prevalence and the disease severity.
Lichtenberg (2006) …nds a positive correlation between cancer incidence and the number of
biomedical publications. Unlike these studies, we use panel data and exogenous variation
in the disease incidence to identify the induced innovation e¤ect, and we also determine the
technological opportunity e¤ect.
Our contribution builds on two connected strands of literature on for-pro…t innovation.
The induced innovation hypothesis originated in Hicks (1932) and Schmookler (1966). Recent
empirical studies of the induced innovation hypothesis in the pharmaceutical industry include
Acemoglu and Linn (2004), which we discuss below, Finkelstein (2004) and Lichtenberg
and Waldfogel (2003). Technological opportunity was examined …rst by Scherer (1965) and
Schmookler (1966), and more recently by Popp (2002) which we discuss below.
The studies most closely related to ours are Popp (2002) and Acemoglu and Linn (2004).
Popp (2002) uses data on energy prices and patenting activity across energy technologies
2

over time and …nds a positive relationship between innovation and both energy prices and
technological opportunity.1 We too examine both induced innovation and the technological opportunity e¤ect. But in contrast with Popp (2002) our main focus is on non-pro…t
innovation and we use data on biomedical publications to measure inventive activity.
Acemoglu and Linn (2004) use the change in age demographics to identify the e¤ect of
market size on pharmaceutical innovation and …nd a positive empirical relationship.2 In
comparison, we use changes in both age demographics and obesity prevalence to identify the
induced innovation e¤ect. Also, whereas Acemoglu and Linn (2004) measure the extent of
pharmaceutical innovation from new drug introductions, which re‡ects for-pro…t production,
we measure it from biomedical publications, which re‡ects non-pro…t production. An additional di¤erence between our work and Acemoglu and Linn (2004) is that our main focus is
not on induced pharmaceutical innovation but on the determinants of medical research.
The methodology we use to estimate technological opportunity builds on the methodology
developed in the studies on patenting by Caballero and Ja¤e (1993) and Ja¤e and Trajtenberg
(1996). In comparison with these studies we derive the estimating equation from a model of
optimal allocation of research e¤ort. This enables us to estimate the structural productivity
parameters. Moreover, the probability that a given knowledge cohort is used in research
depends also on the quality of other existing knowledge cohorts.
Our …nding of obesity-induced innovation is also related to the empirical studies on
preference externalities by Waldfogel (2003) and George and Waldfogel (2003). In these
studies the preference externality arises from racial characteristics whereas in our case the
preference externality is determined by the consumers’ decisions about body weight (to
the extent it is a decision). In a companion paper (Bhattacharya and Packalen, 2008) we
calculate the welfare e¤ect of the induced innovation externality of obesity.
1

Newell, Ja¤ee and Stavins (1999) exploit the changes in energy prices and changes in the cost and energy
e¢ ciency of air conditioners to examine the e¤ect of energy prices on the direction of technological change.
2
DellaVigna and Pollet (2007) exploit the changes in the age demographics to study stock market returns.

3

3

Theory

We …rst present a model of medical research. In the second subsection we discuss why
technological opportunity in medical research is also a measure of pharmaceutical innovation.

3.1

A Model of Medical Research

We distinguish between two types of medical research: drug-related medical research and
other medical research. In both cases, following the induced innovation hypothesis, the optimal research e¤ort is increasing in disease incidence. In the case of drug-related medical
research the research e¤ort is also in part determined by technological opportunity as new
research opportunities are presented by the discovery of new active ingredients. The pharmaceutical research that leads to the discovery of new active ingredients precedes the type
of medical research examined here. The model of allocation of other medical research is a
special case of the model of allocation of drug-related medical research. Therefore, we only
consider the allocation of drug-related medical research in the formal analysis.
We divide drug-related medical research into mutually exclusive categories by the disease
examined in the research and by the active ingredient used in the research. We also lump
together the ingredients by their year of discovery (cohort), denoted by f . We …rst consider
the optimal allocation of drug-related research e¤ort in the disease i in year t across cohorts
f . We assume that the bene…t of research on disease i that uses ingredients from a cohort f
depends on a measure of the baseline productivity of the cohort of ingredients f in research
on the disease i, denoted by aif , on the elapsed time t

f since the initial discovery of the

ingredients, on the extent of the research e¤ort in year t that uses an ingredient from the
cohort f in research on the in disease i, denoted Nitf , on the expected number of people
with the disease i in year t; denoted by Mit , and on other factors, denoted by "itf :
Speci…cally, we assume that the bene…t from research on the disease i in year t that uses

4

an ingredient from the cohort of ingredients f is

Mit

f)

1 (t

e

if

In this expression the factor 1

2 (t

e

f)

2 (t

+ "itf

ln (Nitf ) :

(1)

1

e

f)

represents the lag after the discovery of the

ingredients in the cohort f before the full potential of this cohort of ingredients in medical
f)

1 (t

research on the disease i is revealed. The factor e

represents the eventual decay in

the usefulness of the cohort of ingredients f in medical research as the properties of this
cohort of ingredients become established knowledge.3 We assume that the variable "itf is
observable to the medical researchers and satis…es E ["itf ] = 0.
The range of cohorts f is ff0 ; f0 + 1; :::; tg in year t. The total bene…t from research on
the disease i in year t is the sum of the bene…t (1) over all cohorts:

Mit

t
X

1 (t

e

if

f)

1

e

2 (t

f)

+ "itf

ln (Nitf ) :

(2)

f =f0

We assume that the allocation of research across cohorts of ingredients within a disease is
optimal. Denoting pitf

Pf

Nitf

f =f0

pitf = Pt

Nitk

if

f =f0 f

the …rst-order conditions for the optimum imply that4
1 (t

e

e

if

f)
1 (t

1
f)

e
[1

2 (t

f)

+ "itf

e

2 (t

f )]

+ "itf g

:

(3)

We now consider the optimal allocation of research e¤ort across diseases. We assume
3

We do not model explicitly the e¤ect that the amount of research in the preceeding years may have on
the bene…t from research in a given year. This assumption is innocuous if marginal research in each year
does not in‡uence the quality of research opportunities in future years.
4
Denoting the optimal level of e¤ort by Nitf , the …rst-order condition for the optimum is Mit
if
1 (t

e

f)

[1

e

Nitf
1 (t f )

2 (t

f)

]+"itf

= Mit

e
if 0

1 (t

f0)

h
1 e

Nitf 0

2 (t

f0)

i
+"itf 0

for all (i; t; f; f 0 ) : Denoting citf

e
1 e 2 (t f ) + "itf this condition can be rewritten as citf Nitf 0 = Nitf citf 0 for all
0
(i; t; f; f ) : Taking the sum of both sides of the equation citf Nitf 0 = Nitf citf 0 over all f 0 2 ff0 ; :::; tg
Pt
Pt
gives citf
f =f0 Nitf = Nitf
f =f0 citf for all (i; t; f ) : Rearranging and using the de…nitions of citf and
pitf gives the relationship (3) in the text.
if

5

that the overall bene…t from research in year t is the sum of the bene…t from research in
each disease (see the expression (2)) over all diseases. The overall bene…t is therefore
X

Mit

i

t
X

1 (t

e

if

f)

1

2 (t

e

f)

+ "itf

ln (Nitf ) :

(4)

f =f0

If the allocation of resources across cohorts of ingredients within a disease is optimal, using
Pt
the de…nition of pitf and the de…nition Nit
f =f0 Nitf the expression (4) for the overall
bene…t from research can be rewritten as
X

Mit

i

t
X

1 (t

e

if

f)

1

2 (t

e

f)

+ "itf

ln Nit

pitf :

(5)

f =f0

If also the allocation of resources across diseases is optimal we have

Nit =

X

Nit

i

Mit

Pt

1 (t

e

if
f =f
Pt 0
P
f =f0 f if
i Mit

e

f)
1 (t

1
f)

[1

2 (t

e
e

f)

2 (t

+ "itf
f )]

+ "itf g

(6)

for all (t; i) by the …rst-order conditions for the optimum.
P
The factor tf =f0 f if e 1 (t f )
1 e 2 (t f ) + "itf g in the equation (6) is a mea-

sure of technological opportunity in research on the disease i in year t: Denoting this
measure of technological opportunity by Kit we can rewrite the equation (6) as Nit =
P
Pt
P
Mit Kit : Assuming that Nit > 0 and Kit > 0 for all (i; t)
i Mit
f =f0 Kit
i Nit =
this can be rewritten as

ln Nit = ln Kit + ln Mit +
where

t

= ln

hP

i Nit =

P

i Mit

Pt

f =f0 Kit

i

t;

(7)

:

The empirical predictions of this model are two-fold. First, by the equation (7) the model
predicts a proportional relationship between research e¤ort in a disease and technological
opportunity for research on the disease and a proportional relationship between the research
e¤ort in a disease and the disease incidence. With a di¤erent functional form for the overall
6

bene…t from research both relationships would still be positive but non-proportional. We
allow for this possibility in our empirical framework. Second, the model predicts the relationship (3) between the parameters

if ;

1

and

2

that govern technological opportunity

Kit and the probability that a cohort of ingredients is used in research. We use this predicted relationship to estimate the parameters

if

and the parameters

1

and

2

in order to

construct an estimate of technological opportunity Kit .
As we can only construct a measure of technological opportunity for drug-related medical
research, the relevant empirical prediction of the corresponding analysis for the case of other
medical research is simply a proportional relationship between the disease incidence and the
research e¤ort in the disease. As in the case of drug-related research, di¤erent assumptions
about the preferences would imply that the relationship is positive but non-proportional.
We allow for this possibility in the empirical analysis.

3.2

Pharmaceutical Innovation

Acemoglu and Linn (2004) present a formal analysis of induced innovation that predicts
a positive relationship between the extent of pharmaceutical innovation and the potential
market size for new drugs. While their focus is on the e¤ect of market size on the ‡ow
of pharmaceutical innovation, Acemoglu and Linn (2004) also note a positive empirical
relationship between the stock of drugs and potential market size.
Our measure of research opportunity in drug-related medical research is determined by
the extent of past pharmaceutical innovation. We can therefore examine the relationship
between the extent of pharmaceutical innovation and the potential market size indirectly by
comparing the changes in the relative potential market sizes across diseases and the changes
in technological opportunity across diseases. The induced innovation hypothesis predicts a
positive relationship between these variables.5
5

An advantage of our indirect approach over the direct approach of Acemoglu and Linn (2004) is that
variations in the measure of technological opportunity capture di¤erences in the relative importance of

7

4

Empirical Strategy

We …rst discuss in turn the estimation of technological opportunity, the identi…cation of
the technological opportunity e¤ect, and the identi…cation of the market size e¤ects. The
regression models that we use to estimate the e¤ects are then presented in the last subsection.

4.1

Estimation of Technological Opportunity

In the model of medical research a measure of technological opportunity in drug-related
medical research on the disease i in year t is given by the expression
t
X

Kit

if

e

1 (t

f)

1

e

2 (t

f)

+ "itf ;

(8)

f =f0

where the parameters

if

specify the baseline productivity of each cohort, the parameter

1

governs the eventual decay in the research potential of a cohort of ingredients, the parameter
2

governs the rate at which the full potential of a cohort of ingredients for research is revealed

to researchers, and "itf denotes other factors that in‡uence the productivity of research that
uses ingredients from the cohort f . We assume that E["itf ] = 0 and that "itf is independent
and identically distributed.
The model also predicts the relationship (3) between the probability pitf that an ingredient from the cohort f is used in research on the disease i in year t and the parameters
hP
i
t
1 (t f )
2 (t f ) + "
;
and
.
Denoting
1=
e
1
e
the
if
it
if
itf
1
2
f =f0
relationship (3) may be rewritten as

pitf =

it

=

if

e

1 (t

f)

1

e

2 (t

f)

+ "itf :

(9)

di¤erent drugs. A possible disadvantage of our approach is that the timing of the e¤ect that the discovery
of a new ingredient has on the measure of the technological opportunity does not necessarily coincide with
the timing of the stream of pro…ts from the discovery of the new ingredient.

8

When t

f0 is large, we have that

de…nition of

it

as follows:

1=

it

"

Pt

f =f0

t
X

e

if

0. Applying this simpli…cation modi…es the

"itf

f)

1 (t

1

f)

2 (t

e

f =f0

#

(10)

and also modi…es the relationship (3) as follows:
if

pitf = Pt

1 (t

e

f =f0

if

f)

1

e

1 (t f )

e

2 (t

[1

The econometric challenge is to estimate the parameters
the parameters

and

1

2

f)

+ "itf

e

2 (t

if ,

(11)

f )]

1

and

2.

We …rst estimate

using non-linear least squares applied to the equation (9) while

assuming arbitrary …xed values for the parameters

6
it :

if

and

To estimate the parameters

it

by plugging in the estimates of the

we then use the following iterative procedure:

if

We start by calculating initial estimates of
parameters

1

and

2

as well as arbitrary (starting) values of

if

into the expression

(10).7
Using the estimates of the parameters
2,

we estimate the parameters

holding

it ;

1

and

2

1

and

2

and the estimates of the parameters

1

and

by least squares applied to the equation (9) and

…xed.

We recompute the estimates of
of

if

it

it

by plugging in the estimates of

if

and the estimates

into the expression (10). If the new value of the estimate of

it

is

su¢ ciently close to the old value, we declare convergence. If not, we iterate the previous
step until convergence.
6

We assume that if = 1 and it = 1 for all i; t; f: The estimating equation therefore becomes pitf =
f)
e
1 e 2 (t f ) + "itf : Omitting a multiplicative constant in this speci…cation is both innocuous
and necessary because the true value of the parameter 2 is typically very small and the variation in t f
is limited which make the factor 1 e 2 (t f ) approximately equal to 2 (t f ) in the sample.
7
We assume that if = 1 for all i; f:
1 (t

9

This iterative procedure yields estimates of the parameters

if .

We then generate our

estimate of technological opportunity using the estimates ^ if ; ^ 1 and ^ 2 and the formula

K^it

4.2

E[Kit j^ if ; ^ 1 ; ^ 2 ]

t
X

^ if

f =f0

e

^ (t f )
1

h

1

e

^ (t f )
2

i

:

(12)

Identi…cation of the Technological Opportunity E¤ect

As the variation in technological opportunity over time is likely to be correlated with the
variation in the unobserved determinants of medical research over time, we employ …xed
e¤ects approaches in which the technological opportunity e¤ect is identi…ed by comparing the
changes in technological opportunity with the changes in the research e¤ort across diseases
over time.
The model of medical research predicts that within a disease the distribution of research
across cohorts of ingredients is independent of the total amount of research on the disease.
With a di¤erent functional form for the overall bene…t from medical research this would
not hold. Consequently, changes in the level of drug-related research on a disease could be
correlated with changes in the estimated technological opportunity in research on the disease
even if there was no causal relationship from technological opportunity to the level of the
drug-related research e¤ort.
However, the unobserved e¤ects that in‡uence the level of drug-related research e¤ort
and the unobserved e¤ects that in‡uence the level of other medical research e¤ort are likely
to be correlated. Therefore, if there is indeed reverse causality from the level of research
e¤ort to the measure of technological opportunity, there will be a positive relationship also
between the estimated technological opportunity and the level of other medical research. In
contrast, if there is no reverse causality from the level of research e¤ort to the measure of
technological opportunity, there will not be a positive relationship between the estimated
technological opportunity and the level of other medical research. We can therefore test for

10

the presence of the reverse causality by including the estimate of technological opportunity
also into the analyses of the determinants of other medical research.

4.3

Identi…cation of Market Size E¤ects

As is well recognized in the literature on induced innovation, the causal e¤ect of the potential market size on the extent of innovation cannot be inferred from the relationship between
observed innovation and the observed market size due to the endogeneity of the observed
market size. Acemoglu and Linn (2004) circumvent this problem by examining the relationship between the changes in pharmaceutical innovation and the changes in the potential
market size that are caused by the exogenous changes in the age demographics of the population. The key conditions to the success of this identi…cation strategy are that the e¤ect of
aging on disease incidence varies across diseases, that the age demographics of the population
have changed over time, and that the changes in the age demographics are mostly caused by
changes in fertility and are therefore exogenous to the rate of pharmaceutical innovation.
We follow this general identi…cation strategy in our analyses of induced pharmaceutical
innovation but in constructing the potential market size we take into account both the e¤ect
that the change in the age demographics has had on the disease incidence over time and the
e¤ect that the obesity epidemic has had on the disease incidence over time. As the potential
market size is measured by the disease incidence, we naturally use the same methodology in
the analyses of induced innovation in medical research.
The e¤ect that an obesity-induced change in the potential market size has had on the
extent of innovation may be di¤erent than the e¤ect that an aging-induced change in the
potential market size has had on the extent of innovation if one type of e¤ect has been better
understood than the other or if the change in the age demographics was more expected than
the obesity epidemic. We allow for this possibility by decomposing the changes in the
potential market size into aging-induced changes and obesity-induced changes.

11

4.4

The Empirical Models

We use two types of …xed e¤ects approaches. In one case we include disease …xed e¤ects and
year …xed e¤ects. Using this strategy the identifying variation comes from the variation in
the regressor (either technological opportunity or potential market size) relative to all other
diseases. In the other case we include disease …xed e¤ects and the interactions of disease
class …xed e¤ects and year …xed e¤ects. Using this strategy the identifying variation comes
from the variation in the regressor (either technological opportunity or potential market
size) relative to all other diseases in the same disease class. The parameters of interest will
be di¤erent in these two speci…cations if the elasticity of substitution of research e¤ort is
di¤erent between diseases within each disease class than it is between diseases in di¤erent
disease classes.
The …rst empirical speci…cation that we use to examine induced pharmaceutical innovation is
ln K^it =

M

ln MitT OT AL + …xed e¤ects + "it :

(13)

Here Kit is the estimated measure of technological opportunity for drug-related research on
the disease i in year t.8 The variable MitT OT AL is the potential market size for the disease i
in year t. We measure the potential market size by the incidence of the disease i in year t:

MitT OT AL

5 X
3
X

i;j;k

sAGE
j;t

I
sBM
j;k;t :

(14)

j=1 k=1

In the expression (14) the parameter

i;j;k

is the incidence of the disease i among people in

the age group j who are in the Body-Mass-Index (BMI) group i, the parameter sAGE
is the
j;t
I
share of people in the age group j in year t; and the parameter sBM
j;k;t is the share people in
8

See the subsection 3.2 for why the measure of technological opportunity in drug-related medical research
is also a measure of pharmaceutical innovation.

12

the age group j who are in the BMI group k in year t:9;10 The age groups are 0-18, 18-35,
35-50, 50-65 and 65+. The BMI groups are 18.5-25, 25-30 and 30-50.11
In the second empirical speci…cation for induced pharmaceutical innovation we decompose
the changes in the potential market size into aging-induced changes and obesity-induced
changes. This second empirical speci…cation is
ln K^it =

A

ln MitAGIN G +

O

ln MitOBESIT Y + …xed e¤ects + "it ;

(15)

where
MitAGIN G

3
5 X
X

i;j;k

sAGE
j;t

I
sBM
j;k;t0

(16)

j=1 k=1

is the potential market size in year t for the disease i when the body weight distribution in
year t is set to be the same as the body weight distribution is in the initial year t0 in the
sample and only the age distribution varies across time, and where

MitOBESIT Y

5 X
3
X

i;j;k

sAGE
j;t0

I
sBM
j;k;t :

(17)

j=1 k=1

is the potential market size in year t for the disease i when the age distribution in year t is
set to be the same as the age distribution is in the initial year t0 in the sample and only the
body weight distribution varies across time.12 A positive estimate of the parameter
9

A

is

I
The parameters i;j;k ; sAGE
and sBM
j;t
j;k;t are estimated from data on the disease incidence and from data
on demographics prior to the estimation of the induced innovation model. The data sources are discussed in
the next section. As we use disease and year …xed e¤ects we can ignore population and population growth
in estimating the potential market size.
10
In estimating the disease incidence we allow for the parameter to vary by sex, race (black/non-black),
insurance status (private/not private) and year but for expositional simplicity we omit these issues in the
text. As we don’t measure changes in the insurance rates across time we do not examine the e¤ect that
changes in the insurance rates across time may have on potential market size and innovation.
11
For the age group 0-18 we do not distinguish the disease incidence by body weight and therefore assume
I
BM I
BM I
that sBM
1;1;t = 1; s1;2;t = 0 and s1;3;t = 0 for all t:
12
The decomposition arises as follows. Let Mit0 denote the incidence of the disease i in the initial year t0 :
AGIN G
Let Rit
denote the e¤ect of aging alone on the incidence of the disease i so that if only aging a¤ected the
AGIN G
~ OBESIT Y denote the adincidence of the disease i the disease incidence would be Mit0 Rit
in year t: Let R
it
ditional e¤ect of the obesity epidemic on the incidence of the disease i so that if only aging and obesity a¤ected
AGIN G ~ OBESIT Y
the incidence of the disease i the disease incidence would be Mit = Mit0 Rit
Rit
in year t: Let

13

therefore evidence of aging-induced innovation and a positive estimate of the parameter

O

is evidence of obesity-induced innovation.
The empirical model that we use to analyze of the e¤ect of technological opportunity and
the e¤ect of the disease incidence on the level of medical research e¤ort is13

ln Nit =

K

ln K^it +

A

ln MitAGIN G +

O

ln MitOBESIT Y + …xed e¤ects + "it :

(18)

The variable Nit is a measure of medical research e¤ort on the disease i in year t: As was
discussed in the subsection 4.2, we include the technological opportunity variable also in the
analyses of other medical research because if in the analyses of other medical research the
estimate of the parameter
the coe¢ cient

5

K

K

is close to zero it is an indication that a positive estimate of

for drug-related research is not a result of reverse causality.

Data

We postpone the discussion of the descriptive statistics until the beginning of the next
section. To estimate the disease incidence for each age and BMI group we use the Medical
Expenditure Panel Survey (MEPS) data from years 1996-2005.14 Each subject is followed in
MEPS for two years. For each subject we aggregate the observations in each year into one
OBESIT Y
Rit
denote the e¤ect of obesity alone on the incidence of disease i so that if only obesity a¤ected the
OBESIT Y
AGIN G
incidence of the disease i the disease incidence would be Mit0 Rit
in year t: Because Rit
is small,
OBESIT Y
OBESIT Y
AGIN G ~ OBESIT Y
AGIN G OBESIT Y
~
ln Mit R
: We
R
R
. Therefore, ln Mit R
R
R
it

it

0

it

it

0
it
AGIN G
Rit

it

OBESIT Y
can therefore decompose the aging and obesity e¤ects by using the variables ln
and ln Rit
as regressors. Because the empirical speci…cations include disease and year …xed e¤ects we can replace these
AGIN G
OBESIT Y
variables with the variables ln Mit0 Rit
and ln Mit0 Rit
which in the text are denoted by
AGIN G
OBESIT Y
ln Mit
and ln Mit
; respectively.
13
Because the empirical results show that for medical research the e¤ect of aging-induced changes in the
disease incidence and the e¤ect of obesity-induced changes in the disease incidence are so di¤erent we do not
show the results for the speci…cation in which the two e¤ects are restricted to be the same (the speci…cation
in which the disease incidence is measured by MitT OT AL ).
14
Because the trends in the changes in the age and body weight distributions have been similar across the
developed nations we do not believe that using data on disease incidence, age demographics and obesity for
the United States but data on world-wide publications is a signi…cant concern.

14

observation. MEPS includes a list of self-reported diseases that are coded by the International
Classi…cation of Diseases, Ninth Revision (ICD-9). MEPS does not include BMI information
for years 1996-2000. We therefore use the National Health Interview Survey (NHIS) data
from years 1996-2000 and the match between NHIS and MEPS to obtain BMI information
for the observations in those years. The resulting MEPS data includes 262,958 observations
on 149,737 subjects.15
We use the Surveillance Epidemiology and End Results (SEER) data from years 19752004 to estimate the share of people in each age group in each year.16 For each age group we
use the NHIS data from years 1976-2005 to estimate the share of people in each BMI group
in each year.17
To measure medical research e¤ort as well as technological opportunity in drug-related
medical research we use the MEDLINE database on approximately 16 million biomedical
publications, generally from 1950 to the present. Publications in the database are indexed
by the 2007 version of the Medical Subject Headings (MESH) vocabulary. MESH is a
hierarchical medical vocabulary of over 20000 di¤erent terms.
Because the MEPS data on the disease incidence is indexed by the ICD-9 classi…cation
system and the publications are indexed by the MESH vocabulary we construct a match
between the ICD-9 codes and the MESH vocabulary. We limit the match e¤ort to diseases
for which the MEPS data includes at least 100 observations.18 We do not match ICD-9
codes that include either the word "Other" or the word "Unspeci…ed" in the title because
these ICD-9 codes typically include a variety of di¤erent diseases and are therefore di¢ cult
to match to the MESH vocabulary. Neither do we match diseases in the pregnancy category
15

Except for subjects in the age group 0-18 we exclude subjects without either age or BMI information.
We impute the values for 2005 by assuming that the change in the population in each age group from
2004 to 2005 was the same as it was from 2003 to 2005.
17
We impute the values for 1975 by assuming the the body weight distribution was the same in 1975 as it
was in 1976.
18
We exclude HIV/AIDS because the disease does not appear in the publications database until the early
1980s and because the variations in the incidence of HIV/AIDS are obviously not mainly driven by aging or
the obesity epidemic.
16

15

(class 11), in the congenital category (class 14), in the perinatal category (class 15), in the
symptoms category (class 16), in the injuries category (class 17) or in the services category
(class V). These classes are excluded from the match e¤ort both in order to limit the scope
of our match e¤ort and because of the di¢ culty of matching diseases in these categories. If
a match from an individual disease to a MESH entry/entries is not possible we try to match
a group of ICD-9 codes to a MESH entry/entries.
The matched diseases and their matched MESH entry/entries as well as the unmatched
diseases are listed in the Appendix 1. The match yields 127 separate matches between a
disease or a group of diseases and a MESH entry/entries.19 The 127 diseases belong to 12
disease classes. Because MESH is a hierarchical vocabulary, we also count all research that is
indexed to any subnode of a matched MESH term as research that is related to the matched
disease or group of diseases.20
As the MESH vocabulary has changed over the years we make an e¤ort to check that
the MESH terms for the matched diseases have not changed in a way that would in‡uence
the estimate of the research e¤ort. For the diseases for which the related publications from
a year during the sample period are likely to have been indexed by terms other than the
matched MESH entry/entries we exclude the observations from such years and from any
of the preceding years. In the Appendix 1 the match for such diseases is marked with an
asterisk and the year prior to which any observations are excluded.
To measure the extent of the research e¤ort related to a disease we count the number
of publications that are matched to the disease. A publication may be indexed to multiple
diseases among the 127 matched diseases. We allow for this possibility by counting publications that are matched to more than one disease the same we would count the matches if
19

The matched diseases account for 377,482 of the 745,355 disease mentions in the MEPS data.
We manually remove several matches of ICD-9 diseases to terms for neoplasms in MESH when the same
neoplasm term is also mapped to a disease in the ICD-9 disease class 2 (neoplasms). MESH has 4982 disease
terms. The match maps 1338 terms in MESH to the 127 diseases. 51 of the matched terms are mapped to
2 diseases and one term in MESH is mapped to 3 diseases. All other terms are mapped to only 1 disease.
20

16

each match was from a separate publication.
We identify active ingredients from the Federal Drug Administration (FDA) data on drug
approvals during 1939-2006. As we generally cannot distinguish between active ingredients
and their derivatives in the biomedical publications data, we consider the …rst word in the
list of approved active ingredients to be the ingredient name that we use in our study. This
yields a list of 1448 ingredients.
We search both the title and the abstract of every publication in the MEDLINE database
for each ingredient in the list of ingredients. We set the cohort (year of discovery) of an
ingredient to equal the year prior to the year in which the ingredient is …rst mentioned either
in the abstract or in the title of a publication. In estimating technological opportunity, we
measure the research e¤ort in the disease i in year t that is related to the cohort f by the
number of publications in year t which are matched to the disease i and mention an ingredient
from the cohort f either in the title or in the abstract of the publication. A publication may
be associated with multiple cohorts of ingredients. We allow for this possibility by counting
publications which are matched to more than one cohort of ingredients the same way we
would count the matches if each match was from a separate publication.
We use several strategies to identify and measure drug-related medical research. The
…rst is to classify all publications that are matched to an ingredient as being drug-related
medical research and count a publication that is matched to n di¤erent cohorts of ingredients
as n units of research. The second is to classify all publications that are matched to an
ingredient as being drug-related medical research and count each such publication as one
unit of research. The third is to classify all publications that have a MESH term indexed
together with the "major topic" ‡ag and the MESH quali…er term "drug therapy", "drug
e¤ects" or "pharmacology" as being drug-related research and count each such publication
as one unit of research. We call these three measures as DRUG 1, DRUG 2, and DRUG 3,
respectively.

17

We also use several strategies to identify and measure other medical research. The …rst
is to classify all publications that are not matched to an ingredient as being other medical
research and count each such publication as one unit of research. The second is to classify
all publications that are not matched to an ingredient, that are not indexed are indexed with
any of the MESH quali…er terms "drug therapy", "drug e¤ects" or "pharmacology", and that
are also not indexed with the MESH term "Chemicals and Drugs" as being other medical
research and count each such publication as one unit of research. The third is to classify
all research that is indexed with the MESH quali…er term "surgery" or "transplantation" as
being other medical research and count each such publication as one unit of research. We
call these three measures as OTHER 1, OTHER 2, and OTHER 3, respectively.
As the descriptive statistics discussed in the next section show there is a discontinuous
jump in the share of publications with abstracts in the database from 1974 to 1975. Also, a
number of diseases are indexed with di¤erent MESH terms before 1975 and especially before
1970 than they are after 1975. For these reasons we choose 1975-2005 as our sample period.
When we determine the cohort of an ingredient we use the publications from years 19062005. In estimating the parameters that govern technological opportunity we limit the limit
the range cohorts f to years 1960-2001 because there is a discontinuous jump in 1950 in the
number of publications that are indexed in MEDLINE and because there is a discontinuous
fall in the number of ingredients in a cohort from 2001 to 2002 due to the lag between the
year in which an ingredient is …rst mentioned in the publications database and the year of
FDA approval of the ingredient.21 Because of this lag, because many of the diseases are
indexed with di¤erent terms before 1970, and because in the subsequent analysis our focus is
on the sample period 1975-2005, in estimating technological opportunity we limit the range
of the years t to 1970-2002.
21

We multiply the initially estimated technological opportunity by a factor that compensates for truncation. We assume that the average baseline productivity is the same before and after any truncation point.
P1
Pt 1960 ^
^
^
That is, the estimates are multiplied by f t f =1 e 1 (t f ) [1 e 2 (t f ) ]g=f t f =1 e 1 (t f ) [1

e

^ (t f )
2

]g for all years t

2001. For t > 2001 we also compensate for truncation due to the upper bound.

18

6

Results

We start with the descriptive statistics. All …gures and tables are in the Appendix 2. Figure 1a shows the age and body weight distributions during the sample period. For both
distributions the change has been gradual but the change in the body weight distribution
began more recently than the change in the age distribution. Figure 1b shows the e¤ect that
the changes in the two distributions have had on the disease incidence for each disease from
the beginning of the sample period (1975) to the end of the sample period (2005). For both
variables there is considerable variation in the e¤ect (from -10% to +20%). These identifying
variations are also not too correlated for the e¤ects to be separately identi…ed in most cases.
Figure 2a depicts the count of all publications (All Publications) and the count of publications with an abstract (Publications with an Abstract) by the year of publication. The
graph also shows the count of publications that are indexed to a disease (Publications Indexed with a Disease) and the count of publications that are indexed to a disease that is
matched to an ICD-9 disease by our match (Publications Matched). A publication may be
indexed to more than one disease and, consequently, our match may match a publication to
more than one ICD-9 disease. Therefore, the count of matches of publications to a disease
(Publication-Disease Matches) is higher than the number of publications matched to at least
one disease (Publications Matched).
Figure 2b depicts the count of matches to one of the 127 diseases for the three measures
of drug-related medical research in each year and Figure 2c depicts the count of matches to
one of the 127 diseases for the three measures of other medical research in each year. The
count of publications for each measure is an important determinant of the precision of our
estimates because the variance of the share of publications that are related to a disease is
expected to be inversely related to the count of publications that are related to the disease
and the estimated e¤ects are identi…ed from the e¤ects on the share of publications that are
related to each disease.
19

We …rst estimate the parameters

if

and the parameters

1

and

2

that govern the mea-

sure of technological opportunity using the iterative procedure described in the subsection
4.1. The estimates of the parameters

1

and

2

are ^ 1 = 0:0628 (s.e. 0:0045) and ^ 2 = 0:003

(s.e. 0:0004): Figure 2d shows that the predicted probability that is calculated based on
the estimates ^ 1 and ^ 2 as a function of the ingredient age t

f tracks the mean of the

observed probability closely except for when the ingredient age is 35 and over. The share
of publications that use ingredients aged 35 and over is arti…cially in‡ated by the fact that
the MEDLINE database consists mostly of publications published after 1950 and therefore
our methodology of assigning the year of discovery of each ingredient assigns the year of
discovery between 1950 and 1965 for a disproportionate number of ingredients as can be
seen from Figure 2e.22
We …rst use the constructed measure of technological opportunity in drug-related medical research as a proxy for pharmaceutical innovation to examine the induced innovation
hypothesis for pharmaceutical innovation. Because we expect the variance of the dependent
variable to be inversely related to the count of publications on the disease the observations
are weighted by the total count of matches to an ingredient cohort (measure DRUG 1 ) for
the disease during the sample period.23 The results are shown in Table 1.
Columns 1 and 2 show that when the potential market size e¤ect is identi…ed from
changes relative to diseases within each disease class there is strong evidence for the induced
innovation hypothesis both when the e¤ects of aging and obesity are identi…ed jointly and
when the e¤ects are identi…ed separately.24 Columns 3 and 4 show that when the potential
market size e¤ect is identi…ed from changes relative to all other diseases the induced inno22

Moreover, the precision of the estimates for ingredient ages 35 and over is in‡uenced by the small number
of observations in the data on ingredients aged 35 and over.
P2005
23
That is, each observation is weighted by t=1975 NitDRU G 1 .
24
The interpretation of the point estimates is straightforward. For example, the point estimate in the
column 1 implies that a one percent increase in potential market size increases pharmaceutical innovation
by three percent. The point estimates are consistent with the …ndings in Acemoglu and Linn (2004) who
focus on aging-induced pharmaceutical innovation.

20

vation hypothesis is supported when the e¤ects are identi…ed jointly but the coe¢ cients are
no longer statistically signi…cant when the e¤ects are identi…ed separately. Figures 3a and
3b depict the empirical relationship for the speci…cation analyzed in column 1. The positive
relationship is clearly not a result of outliers. The relationship is even more robust when we
only consider the 50% of the diseases with the most publications. This supports the use of
weighted regressions in the analysis.
Before we examine drug-related medical research and other medical research separately,
we …rst examine the determinants of all medical research. The count of all publications,
denoted by NitALL , that is used in this analysis corresponds to the measure PublicationDisease Matches in Figure 2a. The results are shown in Table 2.25
Columns 1 and 2 show that aging-induced increases in the disease incidence have increased
the medical research e¤ort in the disease. In contrast, there is no evidence of a corresponding
e¤ect for obesity-induced changes in the disease incidence. Columns 3 and 4 show at best a
weak relationship between technological opportunity for drug-related research on a disease
and the amount of total research on the disease. Columns 3 and 4 also show that the
inclusion of technological opportunity variable renders the e¤ect of aging-induced changes
in the disease incidence statistically insigni…cant. However, as can be seen from Figure 3c,
which depicts the …xed e¤ects speci…cation analyzed in column 3, with the exception of the
outlier disease 299 there is a robust positive relationship between aging-induced changes in
the disease incidence and the changes in the overall research e¤ort in the disease. Columns
5 and 6 show that when the disease 299 and the two other children’s mental health diseases
(314 and 315) are excluded, the relationship between aging-induced changes in the disease
incidence and the overall research e¤ort in the disease is again statistically signi…cant.
Because the change in the age distribution has had such an unusual e¤ect on the predicted
25

The observations are weighted by the total count of
matched to the disease during the
Ppublications
2005
sample period. That is, each observation is weighted by t=1975 NitALL . The number of observations varies
^ it = 0 or N ALL = 0:
across columns because an observation is omitted if either K
it

21

disease incidence for the disease 299 (see Figure 1b) and because the dramatic increases in the
number of diagnoses and research interest in the children’s mental health diseases have been
well recognized but without agreement over the causes of this, in the subsequent analyses
we exclude the children’s mental health diseases.26
The results for drug-related research are shown in Table 3.27 There is robust evidence
across the three measures of drug-related research and the two …xed e¤ects speci…cations both
for the hypothesis that technological opportunity is a determinant of the allocation of drugrelated research e¤ort across diseases and for aging-induced changes in the composition of
research. The robustness of the technological opportunity estimate presented in the column
1 is illustrated in Figure 3d. In contrast, there is no evidence in any of the speci…cations
for a positive relationship between obesity-induced changes in the disease incidence and the
amount of drug-related research on the disease. If anything, the results suggest that there
may be a negative relationship between obesity-induced changes in the disease incidence and
the extent of drug-related research on a disease. We return to this issue after discussing the
corresponding results for other research.
The results for other medical research are shown in Table 4.28 For all speci…cations
the estimate of the coe¢ cient on the technological opportunity is much smaller than the
corresponding estimate was for the three measures of drug-related research, and except for
26
Research on children’s mental health diseases has increased dramatically since the early 1990s and this
increase is undoubtedly tied with the increase in the number of diagnoses for these diseases during the same
period. While the unusual increase in the interest in these diseases is well known there is no agreement on
why the increase has occurred. One explanation is that the increase in the diagnoses and the increase in
research to the children’s mental health diseases are consequences of the availability of dramatically better
treatment options for these diseases, especially in the form of better knowledge of the e¤ects of several
drugs such as methylphenidate (ritalin). Methylphenidate was discovered in the 1950s and our measure of
technological opportunity is unable to predict the increase in research to these diseases because the increase
happens 40 years after the discovery of the drug.
An alternative explanation for why the disease 299 and to a lesser extent also the two other children’s
mental health diseases (314 and 315) are outliers is that during the sample period there may have been a
general disproportional increase in research to diseases that primarily a¤ect the children. We plan to explore
this possibility in future research.
P2005
27
For the measure DRUG k, where k 2 f1; 2; 3g, each observation is weighted by t=1975 NitDRU G k .
P2005
28
For the measure OTHER k, where k 2 f1; 2; 3g, each observation is weighted by t=1975 NitOT HER k .

22

…rst …xed e¤ects speci…cation for the most inclusive measure of other research OTHER 1
(see column 1), which is the most likely of the three measures to include also some drugrelated publications, the relationship is also statistically insigni…cant. As was discussed in
the subsection 4.2, the …nding of no relationship between the level of other research and the
technological opportunity in drug-related research is evidence against the possibility that
reverse causality is the reason for the observed positive relationship between the measure of
technological opportunity and the extent of drug-related research.
The results for the measures OTHER 1 and OTHER 2 that are reported in columns 1 and
2 and in columns 3 and 4 also provide evidence of aging-induced changes in the composition
of other medical research across diseases but show no evidence of obesity-induced changes
in the composition of other medical research across diseases. The results for surgery-related
research (the measure OTHER 3 ) in columns 5 and 6 show that the relationship between
aging-induced changes in the incidence of a disease and the extent of surgery-related research
on the disease is positive but not statistically signi…cant. As was the case for drug-relatedresearch, the results for surgery-related research suggest a possible negative relationship
between obesity-induced changes in the incidence of a disease and the extent of surgeryrelated research on the disease. We now examine these relationships with additional analyses
that are reported in Table 5.
In the analyses that are reported in columns 1 and 2 the logarithm of the ratio of the
most restrictive measure of drug-related research and all research is set as the dependent
variable.29 As expected, the results indicate a positive relationship between technological
opportunity in drug-related research on a disease and the share of research on the disease
that is drug-related. Because aging-induced changes are expected to in‡uence drug-related
research and all research the same way, the …nding that there is no statistically signi…cant
relationship between aging-induced changes in the disease incidence and changes in the share
29

Each observation is weighted by

P2005

t=1975

NitDRU G 3 .

23

of research on a diseases that is drug-related research is as expected. However, the point
estimate still leaves open the possibility that drug-related research reacts to changes in the
disease incidence more strongly than all medical research. As in the earlier analyses of
drug-related research the obesity-induced changes in the disease incidence have a negative
but statistically insigni…cant relationship with the changes in the dependent variable. This
suggests that an obesity-induced increase in the incidence of a disease may decrease the share
of research on the disease that is drug-related. A likely explanation is that for the diseases for
which the disease incidence is higher for the obese than it is for the normal weight research
e¤ort is substituted from general research on the disease to obesity-speci…c research on the
disease as the obesity rate increases.
In the analyses reported in columns 3 and 4 the logarithm of the ratio of surgery-related
research and all research is set as the dependent variable.30 The results show a negative and
statistically signi…cant relationship between the share of surgery-related research on a disease
and the measure of technological opportunity in drug-related research on the disease. This
is both evidence against the aforementioned reverse causality explanation for the positive
relationship between drug-related research and the measure of technological opportunity
and evidence that an increase in technological opportunity in drug-related research shifts
research e¤ort away from other types research to drug-related research. The …nding of no
relationship between aging-induced changes in the disease incidence and the ratio of research
that is surgery-related is as expected. The negative relationship between obesity-induced
changes in the disease incidence and the share of research on the disease that is surgeryrelated again suggests the possibility that an obesity-induced increase in the incidence of a
disease shifts resources away from general research on the disease to obesity-speci…c research
on the disease.
30

Each observation is weighted by

P2005

t=1975

NitOT HER 3 .

24

7

Conclusion

We present evidence on how non-pro…t innovation and for-pro…t innovation respond to
changes in the observable determinants of the optimal allocation of inventive activities. Our
results show that the composition of medical research across diseases responds to changes in
technological opportunity and aging-induced changes in the disease incidence. While we …nd
that obesity-induced changes in the disease incidence have not changed the composition of
medical research across diseases, the results suggest that an obesity-induced increase in the
incidence of a disease may have shifted research away from drug-related research and surgeryrelated research on the disease and likely toward obesity-speci…c research on the disease. Our
results also show that the composition of pharmaceutical innovation across diseases responds
to both aging- and obesity-induced changes in the relative disease incidence.
The empirical analysis was in part facilitated by our analysis of a formal model of optimal
allocation of medical research e¤ort. The analysis enabled us to identify the structural productivity parameters that govern technological opportunity. Our research has also demonstrated the research potential of the massive and information rich MEDLINE biomedical
publications database for future research on the economics of innovation.
Our results on medicine and pharmaceuticals and the existing research on induced innovation and technological opportunity in for-pro…t innovation suggest that there does not
exist a fundamental di¤erence between for-pro…t and non-pro…t allocation mechanisms in
terms of how the allocation of inventive activity responds to changes in the characteristics
that determine the optimal allocation: academic medicine is not an ivory tower. Outcomes
under decentralized non-pro…t allocation mechanisms are therefore not necessarily inferior
to the outcomes under for-pro…t allocation mechanisms. We believe that this …nding is important for its implications to economic policy and is certainly worthy of closer attention in
future research.

25

References
Acemoglu, D. and J. Linn, 2004, "Market Size in Innovation: Theory and Evidence from the
Pharmaceutical Industry," Quarterly Journal of Economics, 119, pp. 1049-90.
Bhattacharya, J. and M. Packalen, 2008, "The Other Ex-Ante Moral Hazard in Health,"
Working Paper, Stanford University and University of Waterloo.
Caballero, R. J. and A. B. Ja¤e, 1993, "How High are The Giants’Shoulders: An Empirical
Assessment of Knowledge Spillovers and Creative Destruction in a Model of Economic
Growth," in Blanchard O. J. and S. Fisher, eds., NBER Macroeconomics Annual 1993.
Cambridge: MIT Press, pp. 15-74.
Cameron, A. C., Gelbach, J. B. and D. L. Miller, 2007, "Bootstrap-Based Improvements for
Inference with Clustered Errors," NBER Technical Working Paper No. 344.
DellaVigna, S., and J. M. Pollet, 2007, "Demographics and Industry Returns," American
Economic Review, 97, pp. 1667-702.
Finkelstein, A., 2004, "Static and Dynamic E¤ects of Health Policy: Evidence from the
Vaccine Industry," Quarterly Journal of Economics, 119, pp. 527-64.
George, L. and J. Waldfogel, 2003, "Who A¤ects Whom in Daily Newspaper Markets?"
Journal of Political Economy, 111, pp. 765-84.
Ja¤e A. B. and M. Trajtenberg, 1996, "Flows of Knowledge from Universities and Federal Labs: Modeling the Flow of Patent Citations Over Time and Across Institutional
and Geographic Boundaries," Proceedings of the National Academy of Sciences, 93, pp.
12671-7.
Hicks, J. R., 1932, Theory of Wages. London: Macmillan.

26

Lakdawalla, D. and T. Philipson, 2006, "The Nonpro…t Sector and Industry Performance,"
Journal of Public Economics, 90, pp. 1681-98.
Lichtenberg, F. R., 1999, "The Allocation of Publicly Funded Biomedical Research," in
Medical Care Output and Productivity: Studies in Income and Wealth, LXIII, Berndt,
E. and D. Cutler, eds., Chicago: University of Chicago Press.
Lichtenberg, F. R., 2006, "Importation and Innovation," NBER working paper No. 12539.
Lichtenberg, F. R. and J. Waldfogel, 2003, "Does Misery Love Company? Evidence from
Pharmaceutical Markets Before and After the Orphan Drug Act," NBER working paper
No. 9750.
Newell, R. A., Ja¤ee, A. and R. Stavins, 1999, "The Induced Innovation Hypothesis and
Energy-Saving Technological Change," Quarterly Journal of Economics, 114, pp. 90740.
Popp, D., 2002, "Induced Innovation and Energy Prices," American Economics Review, 92,
pp. 160-80.
Scherer, F. M., 1965, "Firm Size, Market Structure, Opportunity, and the Output of Patented
Inventions," American Economic Review, 55, pp. 1097-125.
Schmookler, J., 1966, Invention and Economic Growth. Cambridge: Harvard University
Press.
Waldfogel, J. 2003, "Preference Externalities: An Empirical Study of Who Bene…ts Whom
in Di¤erentiated Product Markets," Rand Journal of Economics, 34, pp. 557-68.

27

Appendix 1: ICD-9/MESH Match
1.

INFECTIOUS AND PARASITIC DISEASES

GROUP

ICD-9 entry/entries

MESH entry/entries

011
034
052
053
054
070
075

011
034
052
053
054
070
075
110
111
112
132
133
038
074

Tuberculosis, Pulmonary [C01.252.410.040.552.846.899]
Scarlet Fever [C01.252.410.890.823]
Chickenpox [C02.256.466.175]
Herpes Zoster [C02.256.466.423]
Herpes Simplex [C02.256.466.382] *1982Hepatitis [C06.552.380]
Infectious Mononucleosis [C15.604.515.516]
Tinea [C17.800.838.208.883]
Tinea Versicolor [C01.703.295.936]
Candidiasis [C01.703.160]
Lice Infestations [C03.858.211.300]
Mite Infestations [C03.858.211.394]

110
112
132
133
N O M AT C H

Pulmonary tuberculosis
Streptococcal sore throat and scarlet fever
Chickenpox
Herpes zoster
Herpes simplex
Viral hepatitis
Infectious mononucleosis
Dermatophytosis
Dermatomycosis, other and unspeci…ed
Candidiasis
Pediculosis and phthirus infestation
Acariasis
Septicemia
Speci…c diseases due to Coxsackie virus

28

2.

NEOPLASMS

GROUP

ICD-9 entry/entries

MESH entry/entries

150

150-159
Malignant neoplasm of digestive organs and peritoneum
211
Benign neoplasm of other parts of digestive system

Digestive System Neoplasms [C04.588.274]
Abdominal Neoplasms [C04.588.033]
Anal Gland Neoplasms [C04.588.083]

162
171

172

174

179

162
163
171
214
215
172
173
216
174
175
217
179
180
181
182
183
184
218
219
220
221
185
186
187
222
188
189
223

Malignant neoplasm of trachea, bronchus, and lung
Malignant neoplasm of pleura
Malignant neoplasm of connective and other soft tissue
Lipoma
Other benign neoplasm of connective and other soft tissue
Malignant melanoma of skin
Other malignant neoplasm of skin
Benign neoplasm of skin
Malignant neoplasm of female breast
Malignant neoplasm of male breast
Benign neoplasm of breast
Malignant neoplasm of uterus, part unspeci…ed
Malignant neoplasm of cervix uteri
Malignant neoplasm of placenta
Malignant neoplasm of body of uterus
Malignant neoplasm of ovary and other uterine adnexa
Malignant neoplasm of other and unspeci…ed female genital organs
Uterine leiomyoma
Other benign neoplasm of uterus
Benign neoplasm of ovary
Benign neoplasm of other female genital organs
Malignant neoplasm of prostate
Malignant neoplasm of testis
Malignant neoplasm of penis and other male genital organs
Benign neoplasm of male genital organs
Malignant neoplasm of bladder
Malignant neoplasm of kidney and other and unspeci…ed urinary organs
Benign neoplasm of kidney and other urinary organs

200

200-208

Malignant neoplasm of lymphatic and hematopoietic tissue

230

230-234
(none)

Carcinoma in situ

N O M AT C H

29

Respiratory Tract Neoplasms [C04.588.894.797]
Soft Tissue Neoplasms [C04.588.839] *1976-

Skin Neoplasms [C04.588.805]

Breast Neoplasms [C04.588.180]

Genital Neoplasms, Female [C13.351.937.418]
Genital Neoplasms, Male [C04.588.945.440]
Urologic Neoplasms [C12.758.820]

Leukemia [C04.557.337]
Lymphoma [C04.557.386]
Carcinoma in Situ [C04.557.470.200.240]

3.

ENDOCRINE, NUTRITIONAL AND METABOLIC DISEASES, AND IMMUNITY DISORDERS

GROUP

ICD-9 entry/entries

272
274

240
241
242
243
244
250
265
266
272
274

Simple and unspeci…ed goiter
Nontoxic nodular goiter
Thyrotoxicosis with or without goiter
Congenital hypothyroidism
Acquired hypothyroidism
Diabetes mellitus
Thiamine and niacin de…ciency states
De…ciency of B-complex components
Disorders of lipoid metabolism
Gout

275

275

Disorders of mineral metabolism

276

276

Disorders of ‡uid, electrolyte, and acid-base balance

279

279

Disorders involving the immune mechanism

N O M AT C H

256

Ovarian dysfunction

240
242
243
250
265

MESH entry/entries
Goiter [C19.874.283]
Hyperthyroidism [C19.874.397]
Hypothyroidism [C19.874.482]
Diabetes Mellitus [C18.452.394.750]
Vitamin B De…ciency [C18.654.521.500.133.699]
Lipid Metabolism Disorders [C18.452.584]
Gout [C05.550.114.423]
Hemochromatosis [C18.452.565.500.480]
Hepatolenticular Degeneration [C18.452.648.618.403]
Hypophosphatemia, Familial [C18.452.750.400.500]
Hypercalcemia [C18.452.174.451]
Hypocalcemia [C18.452.174.509]
Hypokalemia [C18.452.950.565]
Hypernatremia [C18.452.950.452]
Acidosis [C18.452.076.176]
Alkalosis [C18.452.076.354]
Agammaglobulinemia [C15.378.147.142]
DiGeorge Syndrome [C16.131.300]
*1977Dysgammaglobulinemia [C15.378.147.333]
Wiskott-Aldrich Syndrome [C15.378.100.100.970]

30

4.

DISEASES OF BLOOD AND BLOOD-FORMING ORGANS

GROUP

ICD-9 entry/entries

MESH entry/entries

280

280
281
282
283
284
285

Iron de…ciency anemias
Other de…ciency anemias
Hereditary hemolytic anemias
Acquired hemolytic anemias
Aplastic anemia
Other and unspeci…ed anemias

Anemia [C15.378.071]

Diseases of white blood cells

Agranulocytosis [C15.378.553.546.184]
Granulomatous Disease, Chronic [C15.378.553.774.535]
Eosinophilia [C15.378.553.231]
Leukocytosis [C15.378.553.475]

288

288

N O M AT C H

(none)

31

5.

MENTAL DISORDERS

GROUP

ICD-9 entry/entries

MESH entry/entries

295

299

295
296
309
299

Schizophrenic psychoses
A¤ective psychoses
Adjustment reaction
Psychoses with origin speci…c to childhood

300

300

Neurotic disorders

301
302

314

301
302
303
304
305
314

Personality disorders
Sexual deviations and disorders
Alcohol dependence syndrome
Drug dependence
Nondependent abuse of drugs
Hyperkinetic syndrome of childhood

Schizophrenia [F03.700.750]
Mood Disorders [F03.600]
Adjustment Disorders [F03.075]
Child Development Disorders, Pervasive [F03.550.325] *1981Anxiety Disorders [F03.080]
Dissociative Disorders [F03.300]
*1981Factitious Disorders [F03.400]
Somatoform Disorders [F03.875]
Personality Disorders [F03.675]
Sexual and Gender Disorders [F03.800]

315

315

Speci…c delays in development

N O M AT C H

308
306

Acute reaction to stress
Physiological malfunction arising from mental factors

296

303

Substance-Related Disorders [F03.900]
Attention De…cit Disorder with Hyperactivity [F03.550.150.150]
Developmental Disabilities [F03.550.362]
Communication Disorders [F03.550.350]

32

6.

DISEASES OF THE NERVOUS SYSTEM AND SENSE ORGANS

GROUP
320
332
340
343
345
346
350
361
363
365
366
367
368
371
372
373
375
380
381
386
389
N O M AT C H

ICD-9 entry/entries

MESH entry/entries

320
Bacterial meningitis
321
Meningitis due to other organisms
322
Meningitis of unspeci…ed cause
323
Encephalitis, myelitis, and encephalomyelitis
332
Parkinson’s disease
340
Multiple sclerosis
343
Infantile cerebral palsy
345
Epilepsy
346
Migraine
350-359
Disorders of the peripheral nervous system
361
Retinal detachments and defects
362
Other retinal disorders
360
Disorders of the globe
363
Chorioretinal in‡ammations and scars and other disorders of choroid
364
Disorders of iris and ciliary body
365
Glaucoma
366
Cataract
367
Disorders of refraction and accommodation
368
Visual disturbances
369
Blindness and low vision
371
Corneal opacity and other disorders of cornea
372
Disorders of conjunctiva
373
In‡ammation of eyelids
374
Other disorders of eyelids
375
Disorders of lacrimal system
380
Disorders of external ear
381
Nonsuppurative otitis media and Eustachian tube disorders
382
Suppurative and unspeci…ed otitis media
383
Mastoiditis and related conditions
386
Vertiginous syndromes and other disorders of vestibular system
389
Hearing loss
(none)

33

Meningitis [C10.228.228.507]
Encephalitis [C10.228.228.245]
Myelitis [C10.228.228.618]
Parkinsonian Disorders [C10.228.662.600]
Multiple Sclerosis [C10.114.375.500]
Cerebral Palsy [C10.228.140.140.254]
Epilepsy [C10.228.140.490]
Migraine Disorders [C10.228.140.546.399.750]
Peripheral Nervous System Diseases [C10.668.829]
Retinal Diseases [C11.768]
Uveal Diseases [C11.941]
Glaucoma [C11.525.381]
Cataract [C11.510.245]
Refractive Errors [C11.744]
Vision Disorders [C23.888.592.763.941]
Corneal Diseases [C11.204]
Conjunctival Diseases [C11.187] *1981Eyelid Diseases [C11.338]
Lacrimal Apparatus Diseases [C11.496]
Otitis Externa [C09.218.705.496]
Otitis Media [C09.218.705.663]
Labyrinth Diseases [C09.218.568]
Hearing Loss [C10.597.751.418.341]

7.

DISEASES OF THE CIRCULATORY SYSTEM

GROUP

ICD-9 entry/entries

MESH entry/entries

401

401-405
Hypertensive disease
410
Acute myocardial infarction
412
Old myocardial infarction
413
Angina pectoris
414
Other forms of chronic ischemic heart disease
440
Atherosclerosis
441
Aortic aneurysm and dissection
442
Other aneurysm
426
Conduction disorders
427
Cardiac dysrhythmias
428
Heart failure
430-438
Cerebrovascular disease
444
Arterial embolism and thrombosis
451
Phlebitis and thrombophlebitis
452
Portal vein thrombosis
453
Other venous embolism and thrombosis
454
Varicose veins of lower extremities
456
Varicose veins of other sites
455
Hemorrhoids
458
Hypotension
(none)

Hypertension [C14.907.489]

410
413
414

426
428
430
444

454
455
458
N O M AT C H

Myocardial Infarction [C14.280.647.500]
Angina Pectoris [C14.907.553.470.250.125]
Arteriosclerosis [C14.907.137.126]
Aneurysm [C14.907.055]
Arrhythmia [C14.280.067]
Heart Failure, Congestive [C14.280.434]
Cerebrovascular Disorders [C14.907.253]
Embolism and Thrombosis [C14.907.355]
Phlebitis [C14.907.681]
Varicose Veins [C14.907.927]
Hemorrhoids [C14.907.449]
Hypotension [C14.907.514]

34

8.

DISEASES OF THE RESPIRATORY SYSTEM

GROUP
460
461
463

464

466
477

480

487
492
493
511
N O M AT C H

ICD-9 entry/entries
460
462
472
461
473
463
474

MESH entry/entries

Acute nasopharyngitis [common cold]
Acute pharyngitis
Chronic pharyngitis and nasopharyngitis
Acute sinusitis
Chronic sinusitis
Acute tonsillitis
Chronic disease of tonsils and adenoids

Nasopharyngitis [C07.550.350.700]
Pharyngitis [C07.550.781]
Sinusitis [C08.460.692.752]
Tonsillitis [C08.730.817]
Laryngitis [C08.360.535]
Tracheitis [C08.907.763]
Epiglottitis [C08.730.368.351]
Croup [C08.360.535.365]

464
476

Acute laryngitis and tracheitis
Chronic laryngitis and laryngotracheitis

466
490
491
477
480
481
482
483
484
485
486
514
487
492
493
511
470

Acute bronchitis and bronchiolitis
Bronchitis, not speci…ed as acute or chronic
Chronic bronchitis
Allergic rhinitis
Viral pneumonia
Pneumococcal pneumonia [Streptococcus pneumoniae pneumonia]
Other bacterial pneumonia
Pneumonia due to other speci…ed organism
Pneumonia in infectious diseases classi…ed elsewhere
Bronchopneumonia, organism unspeci…ed
Pneumonia, organism unspeci…ed
Pulmonary congestion and hypostasis
In‡uenza
Emphysema
Asthma
Pleurisy
Deviated nasal septum

35

Bronchitis [C08.381.495.146]
Rhinitis [C08.460.799]

Pneumonia [C08.381.677]

In‡uenza, Human [C08.730.310]
Emphysema [C23.550.325]
Asthma [C08.127.108]
Pleurisy [C08.528.735]

9.
DISEASES OF THE DIGESTIVE SYSTEM
GROUP ICD-9 entry/entries

MESH entry/entries

520

520
521
524

Disorders of tooth development and eruption
Diseases of hard tissues of teeth
Dentofacial anomalies, including malocclusion

522

522
523

Diseases of pulp and periapical tissues
Gingival and periodontal diseases

526

526

Diseases of the jaws

527

527

Diseases of the salivary glands

528

528

Diseases of the oral soft tissues, excluding lesions speci…c for gingiva and tongue

530

530
531
532
533
534
578

Diseases of esophagus
Gastric ulcer
Duodenal ulcer
Peptic ulcer, site unspeci…ed
Gastrojejunal ulcer
Gastrointestinal hemorrhage

531

535

535
Gastritis and duodenitis
555-558
Noninfective enteritis and colitis

536

536

Peptic Ulcer [C06.405.608]
Peptic Ulcer Hemorrhage [C06.405.227.700]
Gastrointestinal Hemorrhage [C23.550.414.788]
Gastritis [C06.405.205.697]
Duodenitis [C06.405.469.275.600]
*1980Enteritis [C06.405.205.462]
Colitis [C06.405.205.265]
Achlorhydria [C06.405.748.045]
Gastric Dilatation [C06.405.748.300]
Dyspepsia [C23.888.821.236]

Disorders of function of stomach

550
560

540
Acute appendicitis
541
Appendicitis, unquali…ed
542
Other appendicitis
550-553
Hernia of abdominal cavity
560
Intestinal obstruction without mention of hernia

562

562

Diverticula of intestine

574

574

Cholelithiasis

577

577

Diseases of pancreas

N O M AT C H

571

Chronic liver disease and cirrhosis

540

Tooth Abnormalities [C07.650.800]
Tooth Erosion [C07.793.763]
Tooth Abrasion [C07.793.707]
Malocclusion [C07.793.494]
Periapical Diseases [C07.320.830]
Dental Pulp Diseases [C07.793.237]
*1980Periodontitis [C07.465.714.533]
Gingival Diseases [C07.465.714.258]
Jaw Cysts [C04.182.089.530]
*1980Granuloma, Giant Cell [C05.500.368]
Salivary Gland Diseases [C07.465.815]
Stomatitis [C07.465.864]
Noma [C07.465.604]
Esophageal Diseases [C06.405.117]

Appendicitis [C06.405.205.099]
Hernia [C23.300.707]
Intestinal Obstruction [C06.405.469.531]
Diverticulum, Colon [C23.300.415.124]
Diverticulum, Stomach [C23.300.415.500]
Cholelithiasis [C06.130.409]
Pancreatitis [C06.689.750]
Pancreatic Cyst [C06.689.500]

36

10.

DISEASES OF THE GENITOURINARY SYSTEM

GROUP

ICD-9 entry/entries

MESH entry/entries

590

590

Infections of kidney

592

592

Calculus of kidney and ureter

595

595
600
601
602
607
610
611
614
620
615
616
618
621
622
623
624
625
617
628
627

Cystitis
Hyperplasia of prostate
In‡ammatory diseases of prostate
Other disorders of prostate
Disorders of penis
Benign mammary dysplasias
Other disorders of breast
In‡ammatory disease of ovary, fallopian tube, pelvic cellular tissue, and peritoneum
Nonin‡ammatory disorders of ovary, fallopian tube, and broad ligament
In‡ammatory diseases of uterus, except cervix
In‡ammatory disease of cervix, vagina, and vulva
Genital prolapse
Disorders of uterus, not elsewhere classi…ed
Nonin‡ammatory disorders of cervix
Nonin‡ammatory disorders of vagina
Nonin‡ammatory disorders of vulva and perineum
Pain and other symptoms associated with female genital organs
Endometriosis
Infertility, female
Menopausal and postmenopausal disorders

Nephritis [C12.777.419.570]
Nephrolithiasis [C12.777.419.600]
Ureterolithiasis [C12.777.725.938]
Cystitis [C12.777.829.495]

600
607
610
614

615

617
628
N O M AT C H

37

Prostatic Diseases [C12.294.565]
Penile Diseases [C12.294.494]
Breast Diseases [C17.800.090]
Adnexal Diseases [C13.351.500.056]

Uterine Diseases [C13.351.500.852]
Vaginal Diseases [C13.351.500.894]
Vulvar Diseases [C13.351.500.944]

Endometriosis [C13.351.500.163]
Infertility, Female [C13.351.500.365.700]

12.

DISEASES OF THE SKIN AND SUBCUTANEOUS TISSUE

GROUP

ICD-9 entry/entries

MESH entry/entries

680

680
681
682
684
690
706
691
692

Carbuncle and furuncle
Cellulitis and abscess of …nger and toe
Other cellulitis and abscess
Impetigo
Erythematosquamous dermatosis
Diseases of sebaceous glands
Atopic dermatitis and related conditions
Contact dermatitis and other eczema

Furunculosis [C01.252.410.868.820.270]

696

696

Psoriasis and similar disorders

698

698

Pruritus and related conditions

700
703
704
705
708

700
703
704
705
708
707
695
693

Corns and callosities
Diseases of nail
Diseases of hair and hair follicles
Disorders of sweat glands
Urticaria
Chronic ulcer of skin
Erythematous conditions
Dermatitis due to substances taken internally

681
684
690
691

N O M AT C H

Cellulitis [C01.539.800.130]
Impetigo [C01.252.410.868.820.504]
Dermatitis, Seborrheic [C17.800.174.580]
Acne Vulgaris [C17.800.794.111]
Dermatitis, Atopic [C17.800.174.193]
Dermatitis, Contact [C17.800.174.255]
Psoriasis [C17.800.859.675]
Pityriasis [C17.800.859.600]
Parapsoriasis [C17.800.859.575]
Pruritus [C17.800.685]
Prurigo [C17.800.674]
Neurodermatitis [C17.800.174.660]
Callosities [C17.800.428.200]
Nail Diseases [C17.800.529] *1979Hair Diseases [C17.800.329] *1980Sweat Gland Diseases [C17.800.946] *1976Urticaria [C17.800.862.945]

38

13.

DISEASES OF THE MUSCULOSKELETAL SYSTEM AND CONNECTIVE TISSUE
ICD-9 entry/entries

MESH entry/entries

710
728

Di¤use diseases of connective tissue
Disorders of muscle, ligament, and fascia

Sjogren’s Syndrome [C05.550.114.154.774]
Scleroderma, Systemic [C17.300.799]
Scleroderma, Localized [C17.300.787]
Dermatomyositis [C05.651.594.297]
Myositis [C05.651.594]

722
726
734

715
721
722
726
734

Osteoarthrosis and allied disorders
Spondylosis and allied disorders
Intervertebral disc disorders
Peripheral enthesopathies and allied syndromes
Flat foot

735

735

Acquired deformities of toe

737

737
717

Curvature of spine
Internal derangement of knee

GROUP

710

715

N O M AT C H

Osteoarthritis [C05.550.114.606]
Intervertebral Disk Displacement [C05.116.900.307]
Bursitis [C05.550.251]
Flatfoot [C05.330.448]
Hallux Valgus [C05.330.610]
Hallux Varus [C05.330.612]
Spinal Curvatures [C05.116.900.800]

39

Appendix 2. Figures and Tables
Figure 1a.
Age and body weight distributions by year.

.8
.6
.4
.2
0

0

.2

.4

.6

.8

1

Body Weight Distribution 1975-2005

1

Age Distribution 1975-2005

1975

1980
0-18

1985
18-35

1990
Year

1995
35-50

2000
50-65

2005

1975

65+

1980

1985

Normal Weight

40

1990 1995
Year
Overweight

2000

2005
Obese

Figure 1b.
E¤ect of changes in age and body weight distributions on potential market size.

30

Effect of Change in Age Distribution and Effect of Change in Body Weight Distribution
During 1975-2005 on Potential Market Size By Disease

Percentage Effect of Obesity
0
10
20

274

250

680
574
592

315
133

276
288

463
295
493

320

684

381

372

614

520

132
52

628
314

540

-10

690

530
350
444 722
275
562
413 726272
550

681

590

112

343 617
34

299

715
302
428 401

466
696

296 454
703 480

698

240

607

735
279
365
710 150366 410
531
363
243 414
371 511
464
461
345
300
734
477
522
242
110
265
301
577
174
361
280 368 386
615487
346
536
527 600
737
53
460
380 610179
200
367
389
528
455 426
595
535
430
526 700
705
691
162
11
458230
373
560
303
172
704
70
340
375
492
332
54
708

75

-10

0
10
Percentage Effect of Aging

41

20

171

Figure 2a.
Publications in the MEDLINE database by year.

0

200000 400000 600000

Publications by Year

1945

1955

1965

1975
Year

1985

All Publications
Publications with an Abstract
Publications Indexed with a Disease
Publications Matched
Publication-Disease Matches

42

1995

2005

Figure 2b.
Matches to drug-related publications in the MEDLINE database by year.

0

20000 40000 60000 80000100000

3 Measures of Drug-Related Research by Year

1975

1985

1995
Year

(DRUG 1) Matches to an Ingredient Cohort
(DRUG 2) Matches to at Least One Ingredient
(DRUG 3) Drugs Indexed as a Major Topic

43

2005

Figure 2c.
Matches to other publications in the MEDLINE database by year.

20000400006000080000100000
120000

3 Measures of Other Medical Research by Year

1975

1985

1995

2005

Year
(OTHER 1) No Matches to Ingredients, Drugs Not Indexed as a Major Topic
(OTHER 2) No Matches to Ingredients, Drugs Not a Major Topic, No Indexed Drugs
(OTHER 3) Surgery

44

Figure 2d.
Predicted probabilities from stage 1 and the mean of observed probabilities.

0

Probability of Use
.005
.01
.015

.02

Ingredient Age and Probability of Use

0

10

20
Age

Mean of Observed Probabilities

45

30

40

Predicted values from Stage 1

Figure 2e.
Number of ingredients by assigned year of discovery.

0

Number of Ingredients Discovered
10
20
30

40

Ingredients Discovered by Year

1900

1920

1940
1960
Assigned Year of Discovery

46

1980

2000

Figure 3a.
^ it on Class Year and Disease …xed e¤ects vs.
Residuals from regression of ln K
residuals from regression of ln MitT OT AL on Class Year and Disease …xed e¤ects
for all 127 diseases.

Technological Opportunity Residual
-2
-1
0
1
2

Residuals for All Diseases

302
302
11

302
302

11
302
11
302
735
75
11
735
34 735
302
361
11
361
34
735
600600600 600 696
361
600
361
600
346
75
722
361
600
696
34
346
487
600
361
272
73511600
696365365
346
361
272
302
487
272
696
75
680
600
361
444 365
70 250
680 680
272
722
680
386 628
250
70
600
361
444
722487 346
696
250
272
34
680
735
365
680
346 600
386
70
250
628
361 444
540
386
272
722
365
250
487
11
628
70
540
680680
511
386
696
550
477
272
444
540
562
346
628
250
550
386
477
511
70
361
540
530 3147575
684
70
550
722
272
477
365
628
511
386
132
110
110
250
530
600
110
110
110
303
110
110
562
562
477
696
343
343
343
110
110
540
562
511
386
110
132
444
628
110
110
110
340
110
272
200
343
365
303
487
11
132
34
343
684
680680
722
477
531
70 530
530
562
550
340
315
132
703
703
343
703
703
703
703
250
303
628
684
511
681
346
110
735
531
132
361
703
614
315
386
343
527
540
314
132
477
703
365
303
684
340
681
511
272
477
531
487
696
614
722
315
132
700
700
332
527
332
303
628
540 314 314
562
681
726
110
700
477
700
531
703
700
332
614
200
332
332
684
75
550
511
700
240
477
700
444
527
332
250
343
242
303
684
530
340
315
386
700
477
531
703
487
365
70
274
562
681
240
600
700
700
577
735
700
361
527
614
242
242
314
274
550
536
681
315
346
389
240
700
132
11
577
734
734
132
303
734
343
332
540
274
171
171
171
722
536
511
315
272
708
734
734
577
531
444
332
614
242
628
52
592
171
350
133
340
681
110
734
734
389
389
132
705
577
454
703
487
34
303
734
302
737
52
52
530
112
715
734
240
386
389
708
522
705
710
577
705
700
365
527
242
52
614
112
540
690
274
680
133
734
734
681
536
511
389
389
477
703
705
361
52
343
426
52
332
614
684
530
690
690
562
372
734
315
300300
300
536
52
708
52
522
52
705
696
577
250
303
243
426
242
530
70
112
274
171
734
350
133
550
372
315
726
300
70
133
300
681
487
536
240
132
389
454
577
444
487
426
426
426
243
200
734
628
112
52
690
592
350
372
722
300
340
52
389
536
300
511
477
705
531
700
303
296
595
243
332
530
174
614
690
52
300
52
372
133
315
389
386
536
272
708
389
522
531
527
296
595
343
301
595
174
301
242
243
112
540
314
52
274
52
350
171
691
372
110
413
413
315
413
133
300
600
132
536
703
454
531
410
373
361
296
303
365
577
530
172
243
595
243
525252 525252
52 171
274
350
562
171
734
299
372
726
315
413
681
162
162
300
477
735
296
373
410
373
705
531
373
303
705
301
426
363
595
174
242
614
112
295
690
295
690
314
592
274
680
550
691
372
162
162
389
240
315
346
536
511
315
296
300
522
696
705
11
531
527
373
301
410
162
303
530
301
487
577
332
363
363
426
174
428
112
428
295
628
428
428
428
428
350
350
698
112
562
726
722
372
340
299
413
133
536
389
373
464
373
301
250
444
34
343
242
595
132
684
243
428
295
75 7575
698
133
274
715
171
70
162
691
681
372
240
315
536
300
454
410
464
299
162
531
464
705
530
345
700
345
428
428
428
363
428
426
200
112
295
70
690
734
540
314
592
592
562
726
386
296
708
703
477
133
511
373
410
345
363
464
303
295
363
577
242
345
595
174
243
428
112
172
265
265
428
265
265
737
295
592
734
274
691
171
550
726
162
301
372
413
132
240
380
464
536
315
389
522
373
300
428
345
162
380
705
112
345
426
487
112
595
265
332
375
295
265
265
628
295
295
314
52
607690607
350
698
366
562
681
301
301
272
380
464
133
530
240
454
428
112
363
531
410
527
373
112
361
303
464
112
595
243
343
299
295
265265
614
265
560
607
375
366
715
274
162
301
691
301
301
301
726
171
722
463
296
4
372
63
590
380
279
363
536
389
279
300
373
150
243
242
150
577
401
150
684
455
200
150
455
150
401
296
150
150
401
150
540
607
75592
350
698
53
162
680
70
296
340
296
171
413
708
381
530
371
463
279
464
371
279
477
428
112
371
240
275
522
315
696
345
511
250
150
380
444
615
279
401
365
133
595
464
162
345
174
455
265
375
455
172
520
458
458
690
458
299
458
458
560
401
401
314
607
520
520
520
520
53
299
734
520
520
715
366
520
110
562
726
550
386
132
428
371
527
463
371
454
279
179
531
401
373
179
615
401
303
615
595
300
279
243
455
487
455
332
265
458
614
458
458
560
737
628
458
607
401
401
401
592
704
704
704
280
366
715
715
296
274
691
301
520
413
171
381
464
401
275
363
371
179
380
615
615
696
463
295
389
315
615
179
705
455
426
455
375
464
458
200
617
455
314
458
401
401
592
704
704
704
704
350
698
53
280
704
280
715
480
715
280
366
366
681
726
550
54
530
463
381
428
112
590
703
381
381
150
372
179
371
615
368
380
303
345
522
240
373
536
595
380
700
493
455
615
577
466
343
458
265
174
133
455
230
617
466
617
172
455
455
560
70
265
737
607
299
704
375
698
280
366
301
704
132
460
301
520
367
279
301
54
54
460
301
401
272
381
346
464
150
381
171
301
454
320
275
320
372
320
320
371
531
710
595
410
240
320
463
511
455
243
466
179
458
242
34
464
493
466
162
617
464
617
493
375
614
466
230
466
690
466
466
314
466
466
466
737
540
737
737
737
314 299 299 299 520 520
53
574
350
53
296
698
562
698
288
366
691
715
367
401
288
367
722
54
610
288
413
460
288
464
708
600
150
574
279
363
320
527
615
381
368
574
11
320
466
444
389
574
240
458
574
275
617
315
615
684
426
464
487
574
200
574
617
332
296
737
628
737
737
734
299
592
53
274
295
280
288
460
288
401
698
386
726
574
463
54
520
112
279
367
428
381
288
460
288
615
179
454
371
477
737
368
696
461
345
380
461
345
461
466
455
737
380
372
361
492
617
179
243
705
463
265
179
279
133
737
480
528
200
430
528
480
430
528
4
528
737
230
614
30
493
737
560
737
265
520
574
737
607
493
53
53
53
299
53
53
53
53
698
375
480
53
295
680
288
366
367
530
681
704
737
340
550
150
610
54
464
737
610
320
275
345
345
345
368
381
460
461
368
461
303
531
466
710
595
171
4
373
250
10
493
735
320
684
492
536
343
458
242
179
240
375
480
200
375
528
464
464
430
375
375
172
314
230
492
493
493
53
493
574
53
715
592
734
574
133
698
350
296
460
288
401
562
276
367
574
132
276
279
53
320
610
54
179
590
708
615
367
413
53
381
363
454
492
492
380
461
710
710
492
710
53
295
522
460
480
617
4
458
492
684
179
320
265
61
243
511
389
480
276
53
276
617
375
276
315
240
426
174
615
276
430
276
430
53
2
430
76
690
480
53
607
493
53
493
296
574
690
75
592
698
53
276
530
367
280
401
691
53
366
480
698
492
150
320
276
480
345
464
590
590
276
527
480
590
54
345
414
526
480
696
414
414
520
414
492
454
455
461
466
381
288
458
480
526
531
371
526
493
493
380
492
179
461
684
373
200
242
460
320
577
275
526
705
276
171
275
463
200
172
275
492
172
615
375
691
133
610
535
614
691
375
691
492
230
691
492
280
540
574
715
698
295
480
288
367
132
560
320
560
492
274
691
280
526
560
480
560
279
610
428
615
722
704
276
345
179
363
345
413
698
272
466
466
200
381
303
275
610
461
461
526
526
54
414
710
493
698
454
414
265
368
710
410
414
595
371
492
414
492
179
200
430
200
617
5
735
372
172
430
617
26
375
275
315
426
430
240
610
487
172
528
430
610
615
464
617
691
430
430
162
332
535
610
610
172
528
610
172
172
610
560
480
460
4
92
628
574
690
690
690
299
528
296
375
350
737
460
535
367367
401
480
560
526
463
526
386
4
560
487
681
174
610
493
93
691
112
280
174
280
464
726
550
280
280
363
590
708
276
493
461
458
276
280
461
368
381
380
5
288
200
371
230
710
698
414
230
617
430
373
526
243
343
367
320
367
230
536
174
389
610
275
460
463
528
230
279
375
463
230
463463
535
535
172
535
463
430
314
460
230
527
520
296
715
574
528
592
528
574
526
288
535
526
530
132
480
535
295
715
535
493
560
230
230
560
562
279
535
230
527
615
560
179
610
610
230
458
466
230
493
366
454
590
454
303
454
590
684
413
367
590
610
200
455
367
454
461
595
610
430
250
710
461
368
230
531
430
276
280
367
179
610
380
288
172
414
380
610
242
367
520
617
535
172
444
710
577
461
535
705
610
690
275
367
698
365
535
511
320
535
607
708
535
614
492
463
230
172
230
70
492
230
133
280
540
574
592
53
607
607
528
460
276
480
492
574
276
320
274
179
150
493
560
466
691
535
703
560
493
454
610
454
200
610
275
340
366
200
704
708
340
560
230
617
477
590
371
461
535
590
54
366
366
265
276
461
340
280
535
371
373
243
522
340
288
340
735
700
610
526
526
526
275
276
315
426
288
288
367
526
314
708
375
528
372
691
288
460
288
698
463
288
54
162
463
492
560
527
480
715
52
574
314
172
734
607
528
375
132
528
401
528
230230
493
174
680
174
528
615
428
681
430
466
230
345
726
535535
617
275
275
413
722
550
363
560
595
696
454
710710
275
560
54
610
380
560
368
368
590
276
340
710
4
617
340
414
340
414
366
61
414
414
275
426
366
710
528
276
461
174
526
389
240
487
526
171
367
367
320
492
698
132
528
460
698
460
280
133
296
592
75
574
737
296
172
607
460
607
288
132
279
480
110
350
480
480
295
463
430
615
386
230
230
466
458
527
560
528
340
696
230
691
303
200
250
726
684
708
455
528
275
346
363
708708
708
710
172
528
295
708
54
314
528
242
368
410
710
522
368
590
410
54
371
343
373
368
710
280
368
528
11
276
705
691
590
536
463
691
279
526
590
366
614
375
366
300
34
162
5
367
367
463
615
26
463
332
367
162
366
367
492
367
366
288
366
460
280
527
698
480
628
715
299
574
172
592
607
401
480
492
530
430
350
607
607
230
466
174
607
715
617
279
200
320
562
345
274
200
710
265
413
690
410
340
708
410
179
368
243
426
371
410
368
380
301
410
577
373
361
275
54
368
381
368
368
371
520
708
607
511
162
590
320
460
590
162
54
463
590
366
366
540
528
460
528
520
133
592
299
299314
296
70
172
460
607
430
617
230
295
320
615
350
458
320
112
684
464
595
272
242
531
172
275
550
726
179
410
607
708
368
704
368
275
410
614
735
174
607
54
340
375
527
536
54
240
526
162
615
726
372
560
460
366
171
726
590
280
288
480
698
715
296
704
704
299299299 299299
460
430
592
1296
492
72
617
574
279
466
690
250
715
684
150
314
696
681
350
607
172
345
243
454
455
691
722
413
610
477
363
274
522
726
371
705
373
280
280
54
461
708
280
389
332
280
617
280
280
367
590
726
280
590
520
698
715
704
704
75
704
704
737
734
460
574
574
617
401
172
607
6
607
07
463
375
428
615
726
527
386
458
174
265
715
150
343
562
275
426
454
350
708
463
276
726
276
444
371
350
375
708
704
381
487
511
520
366
320
520
280
628
288
726
737
590
704
480
592
133
133
430
460
574
617
574
617
492
592
458
172
690
279
607
615
466
455
684
607
200
174
172
696
595
600
735
680
242
560
410
410
179
413
614
410
577
722
275
275
373
550
522
691
691
710
705
454
708
371
461
726
240
540
279
527
350
320
615
413
162
346
704
413
366
366
171
288
704
288
480
698
734
617
53
430
530
314
172
172
200
250
464
150
174
243
410
715
345
410
410
681
691
371
380
560
174
735
726
560
274
536
389
413
413
372
350
340
520
413
413
366
413
288
288
480
133
299
574
430
574
112
690
295
401
458
492
463
615
684
493
265
466
527
150150
150
614
150
346
363
426
413
710
715
708
527
454
461
413
381
511
560
320
70
346
54
132
704
715
350
592
698
480
296
75
430
734
112
296
314
492
615
466
455
466
386
242
595
150
243
174
531
150
179
373
617
522
332
722
705
413
715
550
562
708
487
320
454
300
162
615
240
628
520
704
726
171
520
520
690
715
295
458
265
463
592
684
466
493
250
200
343
295
150
174
363
477
174
577
174
345
375
444
540
610
413
680
413
11
413
301
274
320
381
520
520
698
350
133
690
574
527
375
614
272
426
681
380
522
174
371
722
715
162
279
454
346
511
367
691
520
75
296
350
299
737
133
314
734
458
401
455
466
112
295
200
696
243
373
332
150
375
527
735
240
562
722
708
536
550
389
315
715
592
715
340
698
133
350
690
265
463
428
493
527
200
540
595
242
464
577
363
346
522
365
700
628
346
722
454
615
274
381
372
691
726
520
171
698
530
295
592
250
365
243
703
365
365
426
577
386
150
577
444
380
681
550
680
34
454
511
75
296
698
133
350
690 737
112
401
296
463
684
455
444
466
343
614
295
577
303
373
179
365
705
522
332
375
345
240
162
487
301
722
75
340
726
698
133
350
734
458
684
365
527
200
242
540
592
365
527
617
363
365
361
75
628
708
389
346
300
454
279
511
562
550
274
691
691
350
690
737
265
401
295
444
250
243
426
577
696
200
577
577
705
522
444
363
365
610
681
11
592
454
722
726
171
296
133
350
458
53
455
112
428
365
614
243
684
332
527
444
200
75
577
375
464
386
531
373
477
380
735
240
371
70
345
708
615
381
350
690
458
540
295
242
243
426
295
595
595
595
577
272
592
522
444
363
363
363
371
708
371
346
536
301
562
550
680
340
274
690
458
265
70
455
401
614
684
250
595
595
343
527
527
705
577
522
346
162
345
315
681
381
279
372
726
52
110
426
243
133
75
527
444
373
522
444
527
700
179
628
389
592
346
487
511
300
340
381
722
550
274
171
690
133
530
540
296
243
242
332
684
295
577
386
444
700
380
240
345
562
690
314
265
133
53
75
455
614
243
428
365
303
696
444
444
464
11
592
536
340
301
681
680
550
274
274
274
274
690
314
243
401
426
250
684
444
373
700
444
34
279
274 274
737
75
540
455
614
401
242
332
295
112
684
705
444
628
240
700
380
389
511
300
372
550
562
171
274
265
428
343
179
34
444
373
34
34
735
735
346
34
722
340
734
455
614
426
684
705
34
34
34
487
444
464
600
34
386
477
380
162
487
34
315
681
680
279
75 540 540
401
296
34
684
34
373
162
34
477
700
34
301
550
562
737
265
614
332
426
242
428
250
628
705
684
700
272
240
34
346
389
34
11
536
70
530
112
303
705
365
373
531
464
179
34
536
300
722
681
550
171
614
426
162
70
700
386
34
346
511
315
340
680
737
314614
265
332
426
242
705
343
240
11
372
550
562
614
53
628
428
250
70
464
735
700
361
389
487
681
75 75 54075
540
70
296
696
600
340
301
550
171
332
242
303
703
240
386
511
536
562
70
162
477
389
735
11
346
315
372
550
681
680
314
540
332
628
70
242
343
240
531
300
722
550
562562
314
250
70
735
171
332
303
365
389
487
386
536
372
681
540
628
242
133
530
428
112
70
346
511
301
680
428
70
250
272
11
346
315
171
681
314
332
70
343
112
600
389
477
386
300
722
372
562
628
428
53
530
70
112
487
536
681
540 628
531
700
511
301
171
562
628
530
250
303
700
389
487
11
680
540
314
272
272
346
386
343
365 696735
700
735
272
272
511
132
722
628
272
735
301
700
477
272
536
315
386
250
487
11
511
346
272
272
300386
530
110
343
303
722
52 680
628
600
511
530
250
487
11
477
386
680 680
343
361
346
272
315
722
530
302
734
302
11
302
386
530
303
365
696531
302
302
722
343
696
487
302
361
735
315
250
735
343
302
302
303
11
487
302
703302
315
680
477 272
250
600
11
303
110
110
361
735
735477
680
302
110
531
11
110
735
302
110
696
36570311
11
302
696
696
11
696
361
531
600
302
703
361
302
110
365
703
531361 600
110 703
302
52
302 302
361
600
361
734
361
600
600
302
600
600
361
361
703
302
302
52
5252
132
34

7575

299299
7575 75

734

132

-.15

302

-.1

-.05
0
.05
Potential Market Size Residual
Residuals

Fitted values

47

.1

Figure 3b.
^ it on Class Year and Disease …xed e¤ects vs.
Residuals from regression of ln K
residuals from regression of ln MitT OT AL on Class Year and Disease …xed e¤ects
for the 63 diseases with the most observations.

Technological Opportunity Residual
-.5
0
.5
1
1.5

Residuals for 63 Diseases with Most Observations
302
302
302
302
302
302

628

628

303

-.1

302
11
11
600
600
600
11
600
302
600600 11
600
361 600
361
272 11
361
600
272
361
361600
303
272 444
346
361
11 70 302
272
303 250 250
361
346
600
444628
303
250
361
272
1170 628
628
346
70
365
303
250
361
600
444
272
365
70
303
11
628
250
346
332
332
361
332
696
332
303
628
272
365
332
70
250
444
11
332
696
522
628
350
272 361
346
365
332
600
200
628
250
696
522
70
11
350
272 300300
350 477
444614
200
628
332
696
350
365
303
522
477
250
300
300
300
350
346
240
300
577
70
303
300
614
242
332
477 240240
272
345
361
614
345
350
300
522
696303
112
577
614
242
345
477
480600
295
112
300
691
365
70
614
345
577
345
332
242
112 300
691
691
614
250
444
200
300
691
242
614 303628
350
477
295
112
112
522
365
426
361
11
426
272
426
240
577
426
242
696
614
628303
480
112
332
477
112
345
444
70
426
242
303
112
361
243
413
300
522
243
365
243
303
592 350
240
413
346
413
295272
112
296
243
477
296
296
112
112
250
242
296
614
413
300
112
243
200
172
426
535
530530 530
592
691
112
365
303
696
320
240
480
112
345
522
361
444
112
243
242
332
628704
477
296
112
112
112
240
413
577
426
535
704 530 530
592 350
477
600
295
300
302
242
70
614
592
340
365
243
240
303
413
477
296
242
426
592
350340
346
296
296
531
691
345
243
11
340
480
240
295
300
371
522
250
265
200
265
172
265
535
696
320
413
371
428
265
265
162
531
428
243
162
428
426
265
332
265
265
628
162
296
295
371
428
371
444
361
242
303
428
614
477
531
112
410
162
243
265
174
428
4
58
458
458
162
320
428
410
345
365
265
428
535
428
458
428
592
350
531
240
371
320
200
172
428
428
174
265
428
530
428
458
162
413
296
272
477
320
371
410
243
174
458
428458
340
320
480
371
320
428
691
320
345
615
303
522
162
426
265
458
320
320
410
295
242
70
614
174
458
458
704
295
531
240
410
615
174
265
628
296
320
428
371
320
615
200
458
332
535
162
320
413
296
345
371
275
250
444
401
401
346
174
530
340
493
401
240
615
243
615
265
162
426
458
401
696
530
350
320
590
710
401
531
493
345
615
401
275
242
430
614
530
265
401
704
592
280
715
428
345
477
691
320
522
200
172
535
401
280
280
715
162
710
346
480
401
272
493
493
615
531
240
150
361
615
458
530
150
280
296
480
480
710
371
493
150
303
531
531
371
410
243
320
179
265
150
346
704
628
401
280
715
715
296
480
413
590
480
493
531
275
179
200
179
426
11
430
535
174
150
340
162
401
600
577
577
577
615
466
710
531
371
179
530
458
615
365
696
162
614
430
430
150
401401
350
288
174
710
715
428
577
480
466
577
577
477
179
371
179
242
240
179
179
430
592 592
715
401
288
288
288
288
150
345
493
295
691
112
530
275
320
458
265
615
615
430
430
704704
150
288
162
288
174
590
590
590
288
615
371
493
710
295
179
531
410
275
414
200
172
172
150
401
592 592
280
401
710
715
590
590
296
704
150
413
493
466
480
179
200
577
458
243
444
340
162
430
346
332
710
150 150
288
150
303
363
704
179
200
530
710
522
250
340
240
296
426
172
535
174
430
704
401 401
162
340
715
296
715
345
691
466
340
70
704
172
615
704
430
715
350
276
401
276
276
276
590
704
590
296
363
530
363
363
363
466
466
704
480
200
179
275
242
265
710
172
696
172
696
172
704
535
430
276
288
710
174
428
345
615
200
458
288
363
696
466
410
477
577
704
414
696
340
614
430
172
280
715
280
276
150
590
715
272
276
363
413
363
371
179
276
363
480
531
275
275
320
371
172
426
430
240
535
430
162
430
592
276
276
704
530
276
363
493
691
466
243
275
340
430
710
346
704
628
288
174
303
280
200
276
265
466
275
363
363
430
363
363
715
340
710
401
280
345
280
280
458
696
363
280
414
466
288
531
414
275
414
577
710
535
276
276
332
280
590
615
413
250
414
414
414
531
179
295
242
414
522
363
361
615
174
276
11
288
174
530
696
414
179
414
493
410
691
288
480
430
414
340
172
275
414
426
710
240
276
162
276
710
276
715
710
350
340
715
150
174
458
715
346
590
371
295
276
295
280
172
243
275
410
410
414
535
614
276
340
276
280
704
530
696
200
590
414
430
275
466
410
363
414
444
288
320
577
414
410
363
288
288
162
288
162
401
428
615
414
715
413
414
179
493
410
280
275
531
535
340
295
276
174
162
288
346
715
592
710
288
303
174
530
296
414
414
590
276
410
363
466
466
265
340
480
414
477
426
410
162
363
288
280
696
150
345
250
715
275
275
430
179
493
410
242
275
522
371
162
276
365
363
240
615
288
340
592
710
401
530
350
458
200
691
590
363
535
243
466
363
414
414
480
276
710
332
628
615
275
275
715
413
493
410
280
577
320
295
614
363
371
715
280
530
150
430
272
179
340
275
295
172
535
426
363
70
276
480
276
363
710
592
174
275
493
691
410
531
590
466
466
480
276
710
162
295
710
592
250
350
200
615
345
242
371
265
179
715
410
522
363
112
363
466
477
174
280
340
704
715
530
430
340
174
535
275
413
200
493
363
577
300
276
493
493
466
276
346
710
11
715
288
401
458
150
150
340
243
410
493
590
715
614
466
466
280
480
590
240
280
280
530
696
428
150
150
615
150
174
150
535
296
150
179
172
493
691
276
493
280
280
296
280
332
590
615
280
710
590
590
710
592
430
150
350
179
410
275
410
320
174
715
340
590
280
592
250
365
615
410
413
522
426
363
715
444
493
162
295
628
590
535
458
535
265
345
600
365
295
410
577
295
200
577
493
480
710
710
288
590
430
401
535
696
530
365
172
150
275
410
691
531
715
493
493
493
715
288
288
615
174
340
179
296
577
242
243
371
410
691
350
162
477
240
710
288
590
590
172
704
535
200
295
346
614
413
174
480
531
710
288 592
592
172
365
365
174
150
150
577
715
295
430
172
458
535
530
250
530
530
174
346
522
320
696
615
172
426
691
200
332
480
615
11
628
592
265
272
179
295
174
295
413
350
413
346
413
413
295
340 340
430
401
535
172
172
172
615
345
243
365
365
614
340
174
577
444
162
361
413
413
444
172
242
346
413
240
295
458
535
428
172
200
371
522
691
174
480
430458
535
250
365
615
70
413
413
413
401
426
577
365
320
350
413
704
696
265
295
531
577
296
413
458
444
200
295
522
243
444
365
11
530
592
346
332
477
628
430 430
401
250
242
614
70
691
365
240
615
340
365
200
444
345
691
371
162
531
592
577
577
480
350
426
70
179
691
295
444
320
265
428
522
365
346
704
401
592
243
272
696
691
200
11240
480
458
444
242
614
70
300
577
444
628
240
477
250
577
332
296
477
340 350
426
200
691
522
295
371
477
70
345
592
112
346
480
320
592
530
70
444
200
691
444
458
704
265
614
243
577
531
531
401
428
242
70
691
480
615
70
70
691
444
162
401
426
70
243
444
444
577
371
477
250
200
522
200
592
480
346
350
303
365
444
628
320
704
696
428
614
243
444
444
332
265
530
345
296
458 704
401
242
444
179
179
371
426
70
243
162
11
592
240
350 350
614
600
522
444
112
531
477
458 458
531
320
428
243
272
250
371
361
346
265
614
243
696
70
162
346
426
628
112
296
242
243
696
696
522
300
345
365
332
70
240
371
320
614
696
162
428
530
265
70
70 11 112
426
522
320
614
530
350350
250
628
600
696
240
265
531 346296477
614
426
522
320
332242
477
614
70345
265
242
522
240
426
628
428
300
614
303
428
250
11 240
112
345
350
296
272
477
242
240
428
332
350 350
696
365
70346346
250
345
242
296
477
628 426628
11600112
242250
300
272
345
296
332
628
272
346
272
345
361
272
11
272
332 303
250
300
272
346
628628
600
272
272
272
361
11
250
332332
302 302
365302302
302 272 302 302302
303
302
302 112
300
250
11
361
302 112300
332
250
11
600
302
332 303
302
300 361
11
303
365 112112
302
300
11302
361
600
302
11302
303
302
11
361
302
11 302
361
303
361
361
361361
303
600
302
600
600
600
600
600
600
600

-.05

0
.05
Potential Market Size Residual

Residuals

Fitted values

48

592

.1

Residuals from regression of ln

NitALL

^ it
on ln K

Figure 3c.
, ln MitOBESIT Y ; and Class Year and Disease …xed e¤ects vs.

^ it , ln M OBESIT Y ; and Class Year and Disease …xed e¤ects
residuals from regression of ln MitAGIN G on ln K
it
for all 127 diseases.

Residuals for All Diseases
1

734
700
700

314

-1

All Research Residual
-.5
0
.5

700 700
700

3434
34
332
75
301
734
715
684
562
536536
332705
75
332
250
250455 735 34 332
705
314314
332
332
562
536
705
734
562
314
715
314
428
250
463
332
550
562428
455
680
536
455 274
34
132
536
562
550
463
526
250265
680
536
265
562
428
734
301301
461715
314 680
301272
314 54 132
680
34 75
75
487 536
700
705 332
299
691
737
735
726
617 737
562
455
464
574
365
48775715
380
536
734680511
365
531
715
250
574
132
428
705
464
299
299 299
75
54132
705
550
372
52 617617
466
595
735
700
734
461
715
75
463
511
455
705
455
690
493
301
272
75
698
75
735
75
372
302
365
332
372 463
314
132
414
272280
735
302
493
703
684
70
680
54132
132 230
536
230
367
592
705 34110372
70
617 343
526
302
681
414
511
700
133
531
75
299
380
592
380
735
722
461
371
455
691
302
737
705
365
531
696
600
414
610
493
280
380
531
414
272
461
530
332
700 314
367
487
365
464
722
428
466
302
550
332
110
296
303
735
343
562
592
493
737
680
428
428
737
75
511
367
704
250
250
681
493
477
617
133
302
274
70
461
698
698
343
295
295
274
715
550
698
75
133
265
380
698
296
132
574
295
590
477
530
698
70
54
250
574
274
528
461
375
200
722
610
230
610
368
454
691
461
454
520
550
684
492
511
464
296
511
314
700
250
295
274
464
332
372
487
365
531
174
550
332
200
381
302
735
610
592
715
112
174
726
684
54
250
272
34
590
530
734
373
230
265
430
461
280
371
464
617
463 684
610
54
296
230
511
617
368
295
531
280
272
680
698
171
487
230
592
279
700
372372
53
372
296
112
265
493
279
530
34
52
526
367
230
511
380
574
600
460
413
600
332
461
174
617
110
735
696
380
684
274
531
710
715
477
174
381
200
492
463
684
511
680
610
734
296
681
681
531
461
454
315
200
684
52
361
361
610
367
460
493
386
430
526
430
550
520
53
526
53
367
691
487
430
600
430
371
530
200
171
52
296
302
511
54
536
430
536
200
413
454
70
464
70
162
375
368
487
493
531
708
300
162
110
110
296
380
274
461
703
527
174
460
530
300
737
520
171
684 684
133
373
371
536
715
386
302
162
455
617
276
414
560
691
455
200
615
133
52
279
710
710
340
386
302
464
531
174
617
340
240
34
520
171
171
520
607
617511
367
704
735
691
531
430
200
680
698 75
346
680
367
466
696
595
413
288
590
279
615
300
200
296
171
70 70 70 70
610
54
562
386
250
466
272
375
480
265
200
70463
46370
617
373
454
681
617
386
296
371
174
389
690
34
303
345
715
560
691
477
703
530
430
696
511
34
296
684
133
577
373
272
272
681
466
710
487
722
414
430
493
430
715
112
375
530
375
34
296
520
527
343 296
726
162
726
230
296
466
386
617
480
371
340
550
520
303
722
380
681
458
493
493
696
174
464
301
389
708
162
526
681
428
279
414
413
11
230
531
280
615
708
527
340
300
171
132
460
365
373
600
458
414
461
200
112
171
550
371
320
371
466
230
242
162
413
487
574
737
690
52617
492
386
527
526
303
361
301
691
250
243
345
243
242
288
737
288
527
315
528
332
11
110
607
607
303
726
527
367
681
592
592
368
444
276
526
243
680
703
511
574
366
296
320
375
320
53
540527
684
53680
680
303
361
734
600
428
704
464
371
375
527
34
110
577
704
527
426
243
274
710
477
288
480
690
340
520
300
373
350
480
380
295
477
480
691
460
574
332
550
389
133
240
520
110
302
366
401
162
401
527
350
413
726
279
681
315
110
520
70
301
386
373
70
363
493
288
243
691
112
288
615
704
276
171
315
375
381
340
343 53 52
302
610
171
346
272
574
243
272
243
691
242
477
458
590
681
174
300
315
171
5352
734
615
617
492
704
487
367
361
380
458
250
375
380
274
380
414
401
531
288
315
350
705
171
52296
610
301
345
527
279
272
607
560
715
250
296
401
458
413
696
280
492
240
11
527
520
520
296
5252 52
373
726
528
361
368
444
243
493
363
595
704
715
410
361
276
112
288
710
172
615
708
11
464
520
133
698
300
690
614
389
680
302
463
722
535
426
112
696
288
413
243
530
536
366
296
480
464
628
133
628
133
346
460
708
726
367
401
458
691
691
200
600
265
410
279
371
280
595
174
430
520
381
737
520
511
492
708
368
464
703
243
242
595
590
300
172
430
708
350
240
53
690
300
296
343
295
243
401
410
428
522
708
11
560
684
172
162
530
389
299
607
610
389
381
345
562
464
681
346
592
275
708
592
243
179
274
461
302
242
265
522
414
276
288
708
288
690
705
11
690
296
492
301
200
527
368
410
162
410
735
274
112
487
401
458
455
174
595
346
300
75
540
110607 5353
110
698
171
132
303
380
401
373
303
466
461
230
722
162
595
172
172
600
426
703
346
315
346
11
628
133
684 737
110
70
577
426
303
704
303
272
466
535
696
413
560
366
531
240
343
171
528
386
386
366
368
458
200
386
726
303
454
522
444
530
242
414
535
112
458
710
460
346
458
162
458
240
628
628
300
70
614
343
53
346
527
366
230
361
455
250
361
487
276
522
413
112
4
01
722
320
628
343
361
340
340
272
361
444
275
480
595
401
454
522
242
11
401
528
574
574
315
240
527
75
480
171
343
53
700
110
528
303
540
455
275
288
574
590
454
708
530
332
288
172
696
528
276
464
34
296
607
684
361
200
722
373
577
735
386
240
280
265
710
361
52
477
288
460
531
150
230
340
698
53
52
614
527
345
54
346
345
345
535
172
726
562
276
274
704
698
366
240
302
628
372
734
240
300
527
463
492
480
303
722
272
363
726
380
696
458
242
708
426
242
112
528
276
454
11
375
614
162
320
690
607
607
52
614
53
54
346
279
466
230
522
511
303
243
703
295
279
444
350
276
363
150
240
540
614
343
52
303
340
492
560
380
401
458
410
708
250
522
595
240
371
614
112
53
696
454
288
464
240
734
302
460
350
526
367
466
710
288
350
300
577
592
522
172
530
595
528
614
700
345
381
343
698 463
343
386
722
615
150
704
272
350
703
691
179
455
275
413
535
280
174
112
444
430
179
528
346
528
705
389
11
389
320
320
617
300
698
343
29952
540
540
690
133
375
350
373
464
466
401401
363
696
162
628
332
522
242
444
365
150
162
240
381
350
350
350
296296
577
350
735
179
345
615
577
574
265
454
703
345
275
112
560
172
381
708
540
179
340
11
372
11
375
480
296
350
684
628
734
343
527
345
345
373
345
708
562
363
595
590
522
426
172
522
414
704
361
455
428
531
389
389
320
110
53
540
110
577
350
373
279
460
410
477
428
112
590
240
389
179
340
162
480
110
540
690
540
492 53
492
560
389
346
300
371
426
150
696
595
458
493
461
592
444
320
560
279
372
690
614698
381
340
560
350
426
600
275
454
715
279
477
535
150
179
242
373
535
172
703
428
444
460
615
279
133
628
315
735
722
240
314
527
179
560
340
726
615
54
735
381
133
590
703
466
150
150
365
172
536
444
426
708
276
628
389
480
628
526
690
345
466
698
455
410
280
522
112
428
375
430
363
454
381
363
320
577
366
463
628
133
560
350
615
346
698
681
363
477
595
112
535
444
367
373
150
276
368
615
492
628
320
607
617
343
299 52
150
381
574
279
150
243
710
380
280
487
560
363
703
280
274
444
274
426
426
276
401
607
240
11
389
614
366
150
614
314
110
133
301
179
722
275
363
715
373
595
540
265
413
172
275
11
600
389
150
680
480
320
381
690
480
540
350
132
607 386
389
375
132
303
708
303
708
346
275
590
410
410
381
592
710
171
303
179
413
174
174
179
477
703
162
520
320
684
350
737463
607
528
704
614
444
363
346
363
346
242
458
276
345
112
428
691
444
366
366
179
230
240
680
698
560
110
53
110
381
492
560
350
345
366
454
363
466
410
275
691
464
179
250
530
535
703
535
444
477
536
373
710
386
295
726
574
363
345
577
628
614
540
540
628
690
511
480
301
726
426
320
600
363
240
368
300
295
710
295
242
274
414
367
345
171
150
426
463
340
628
528
737
315
460
526
150
690
607
560
454
279
320
275
590
493
274
5
90
275
275
242
303
535
455
303
428
454
179
275
735
577
704
511
520
614
366
366
577
366
389
53
480
614
410
530
610
590
295
535
276
250
288
428
414
710
528
444
179
628
492
150
380
162
299
314
480
607
737
540
610
480
527
200
11
365
363
410
413
681
242
590
595
280
522
426
11
430
574
340
150
492
301
528
460
366
614
381
607
340
610
179
703
275
426
477
592
600
691
458
595
363
413
522
522
150
172
366
275
528
690
722
430
540
577
540
299 53463299
734
315
705
607
11
11
366
464
560
346
302
696
363
179
371
466
574
295
288
274
536
363
535
592
265
487
444
179
320
428
708
368
303
150
320
375
680
607
299540
381
528
375
371
615
410
477
150
279
614
11
280
373
174
460
410
458
315
381
265
710
276
444
401
1735
363
79
577
315
320
577
562
614
560 734
463 463 463 540
301
722
381
460
464
454
132
295
171
466
493
600
174
710
371
410
150
487
172
526
368
430
722
363
562
511
480
343
690
734
614
375
726
735
401
681
413
426
413
112
320
615
460
600
617
614
299
607
614
200
315
279
574
371
279
454
401
243
410
710
112
511
426
375
698
240
295
302
710
179
315
540
734
373
722
132
492
705
315
315
320
350
577
615
684
363
371
275
315
363
477
600
242
381
595
361
275
179
366
230
320
375
726
614
705
386
607
492
577
560
480
610
315
132
179
600
401
458
590
320
592
365
477
615
466
600
375
53
735
300
365
480
275
628
710
365
275
274
493
595
242
265
522
413
458
595
179
577
275
574
366
480
492
314
272
340
560
410
274
288
600
492
493
595
288
610
526
303
346
361
361
681
540
726
607
628
607
70
480
301
389
230
340
426
703
590
735
276
696
389
174
528
242
615
172
367
455
112
426
710
703
540
275
303
460
150
381
680
615
363
279
346
592
530
577
458
373
592
577
288
346
454
315
414
628
528
458
361
531
345
615
372
276
577
722
314
343
492
492
690
301
301
240
171
150
444
371
628
150
615
562
174
681
615
726
458
703
522
528
430
455
365
531
444
276
375
381
737
550
444
527
386
615
368
696
696
615
522
560
444
614
526
389
366
389
690
299
698
705
240
200
150
340
172
444
150
272
590
295
458
410
535
368
595
531
444
133
690
171
722
11
722
540
315
540
540
133
389
240
301
380
179
172
368
279
75
179
458
444
526
444
373
705
460
708
540
560
526
301
375
276
276
726
530
11
179
413
595
242
600
466
528
426
275
466
368
426
628
466
361
230
53
577
690
366
628
540
690
610
690
460
460
460
276
150
454
704
681
410
11
368
274
368
367
315
346
361
343
737
133
600
734
350
610
592
590
703
172
413
367
696
600
332
430
265
112
710
426
365
531
691
110
275
460
410
614
726
345
162
617
320
301
350
562
365
340
295
288
314
345
172
179179
243
368
535
243
528
363
366
366
560
704
614
320
684
53 171171
11
366
734
110
628
150
340
600
345
389
530
574
295
737
53
710
265
279
726
696
280
615
426
536
577
179
550
295
275
346
343
577
526
389
610
704
492
299
492
314
560
628
280
726
527
477
172
477
477
366
172
367
592
250
243
428
295
365
368
615
11
574
346
375
722
381
314
540
315
300
737
179
172
11
454
172
401
577
295
295
535
389
590
371
574
368
315
477
365
315
386
577
373
614
345
52
299
320
480
527
530
715
590
458
430
455
413
535
426
428
361
600
526
361
373
162
681
617
680
52
463 684
684
690
240
301
528
279
560
363
527
704
530
461
530
477
696
590
179
413
265
535
371
243
700
279
34
363
302
492
540
320
389
607
726
172
372
280
710
528
367
691
132
401
288
703
414
577
696
366
477
726
592
230
480
562
607
366
722
480
386
343
150
11
54
280
461
426
368
54
522
681
380
346
265
280
410
428
444
466
691
340
276
272
560
610
737
70 53
690
302
600
172
590
368
243
295
133
522
600
426
455
703
365
368
410
386
680
343
320
389
700
200
299
426
595
275
680
315
595
522
595
710
492
460
363
303
610
708
150
454
460
350
715
628
461
172
535
172
242
243
628
466
112
368
132
410
345
366
726
276
577
526
737
314
607
70
463
276
350
363
530
461
477
414
343
607
590
371
610
413
243
410
615
528
361
614
272
272
492
300
444
174
340
560
430
174
372
522
380
681
460
368
562
346
315
410
162
314
614
722
75
722
607
276
365
460
615
295
265
242
414
705
265
345
574
389
454
381
366
380
375
511
704
737
54
375
386
162
704
530
560
280
280
172
477
535
691
426
696
373
275
295
345
708
681
381
550
150
371
600
710
52
11
595
295
361
522
487
230
365
577
480
372
737
520
320
315
381
528
133
345
454
710
477
595
681
681
243
243
444
681
460
460
34
386
375
386
162
704
288
535
315
172
493
132
477
265
401
230
466
710
315
133
345
610
520
492
276
460
200
375
530
715
703
242
280
428
368
466
410
401
132
610
562
70343
381
110
628
230
345
280
401
522
242
365
243
487
592
373
704
132
722
302
345
734
11240
550
607
530
174
350
715
288
710
458
487
410
361
614
386
734
737
562
464
444
340
276
280
414
430
590
455
343
592
560
735
460
162
704
600386
684
171
381
386
463
708
279
464
735
492
535
414
401
493
365
458
562
230
315
700
75
373
526
734
343
463
171
372
162
133
371
280
288
361
132
265
280
536
454
365
110
70520
300
708
381
704
414
530
274
265
696
243
361
401
610
346
562
520
320 320
520
110
240
132
600
174
34
174
477
265
350
265
615
401
708
684
704
371
574
280
522
340
389
708
722
430
710
691
274
454
458
607
696
366
276
704
617
52
299
690
607
240
381
722
110
520
34
690
340
112
691
242
493
696
454
590
454
132
314
540
52
492
276
320
174
280
365
414
274
280
361
112
726
614
536
367
681
133
314
295
592
592
303
75
70
628
372
350
540
174
368
493
371
132
345
726
52
343
463
314
386
340
162
250
299
346
295
373
367
54
11
372
562
288
414
340
301
274
367
401
367
737
684
386
11
371
703
368
527
454
466
162
368
401
162
722
560
381
299
520
132
162
162
332
691
487
340
243
272
560
54
680
617
700
520
520
171
680
454
461
734
361
250
536
531
299
684
372
386
722
550
371
600
528
174
112
162
371
703
550
133
466
487
54
367
346
133
133
301
240
698
705
550
430
174
413
562
242
455
265
615
696
295
367
511
698
480
737
461
162
361
414
350
250
230
302
303
240 607
386
464
350
280
265
243
455
487
737
684 70 53
133
464
340
174
75
274
550
242
493
696
696
466
401
54 343610
480
110
372
600
430
112
461
174
550
265
371
737
536
350
365
592
230
726
463 70
492
705
34
708
375
726
371
230
295
737
414
520
531
590
243
487
132
279
346
343
698
550
430
430
110
413
274
314
590
628
389
375
386
200
715
414
414
54
314
615
684 301
300
372
722
734
704
520
527
361
413
365
52
708
526
511
299
690
365
511
52
698
550
265
696
365
373
52
34 372
531
458
526
698
550
112
414
455
617
737
700
463
520
171
174
703
265
590
54
460
302
726
562
371
477
530
698
703
274
493
279
133
592
526
54610
610
463
698
413
487
250
487
737
715
346
691
428
708
610
7070
53
34
112
600
530
112
380
610
511
492
480
710
288
690
458
132
735
171
461
54
343
300
240
11
550
200
530
592
696
466
303
737
734
274
700
590
367
380
735
463
526
380
75
562
272
493
487
367
363
301
463
70
53
372
487
455
428
380373
511
52
299
171
240 389
461
574
413
272
526
367
373
133
272
428
528
617
430 200
414
592
132
511
302
592
133
301
698
375
715
531
272
272
303
520
480
530
272
550
466
54
511
610 301 52
698
112
520
230
691
700
372
595
455
454
536
735
700
461
461
527
681
705
250
302
301
54
299
303
698
487
734 200
200
574
550
428
592
53
464
132
367
680
550
272
574
380
705
110
288
461
110
300
680
464
274
536
302
302
52 301
705
464
715
274
691
455
550
550
380
288
715
367
301463
574
726
617
705
458
230
526
303
301
527
250
332
464
332 296
200
428
7070 463
372 300
722
715
493
691
464
230
428
735302
461
455
708
617
303
200
705
230
477
272
493
536
574
595
735
250
343302 34 463
299
466
250
461
527
272
493
487
70 70
705
531
530
536
735
734 110430332
715
493
302 700
527
53684
428
681
735
52
574
690
279
34
75
527
681
536
110
332
380
300
531
680
132 302
428
691380
511
75
562531
705
681
700 314
274
34314
34 698
75 684
715
200
715
200
705562
34 34
487 562
617
75
428
375 735
531
461
691
700
132
536
53
464
531
531
171 296
680 715455493 279 380 680314
75
705 464715
250
75 75 34
314
314
430
171
455 617
250
511
332
562
735
332
250
684
455 617511
562
332
34
617
536 250 700
34
536
75 75
332
332
332
734
700 680536
332
684 296
296
296
680
296
734
314
700

487
700

734
700
700
700

-.1

-.05

0
.05
Potential Market Size Residual

Residuals

Fitted values

49

.1

Residuals from regression of ln

NitDRU G 1

on ln

Figure 3d.
, ln MitOBESIT Y ; and Class Year and Disease …xed e¤ects vs.

MitAGIN G
MitAGIN G

^ it on ln
residuals from regression of ln K
, ln MitOBESIT Y ; and Class Year and Disease …xed e¤ects
for the 63 Diseases with the most observations.

1

Residuals for 63 Diseases with Most Observations

DRUG 1 Research Residual
-.5
0
.5

365
414
414
265
414
265
365
265
365
414
371
265
577
414

272
272
272
272
272

413
296
296

280
365 365
577
272
280 531
303
466
614 296
430
272
365
340
300
250
600
614
577
430 296
466
413
272
340
414
295
696
272
426
413
250
272
531 363 614
371
413
320
430
295 592
302
332
276250 250
346
477
371
592
531
363
696
265466
430
332
413
535
346
295
296
346
577
243
691
430
401
444
414
303
458
414
430
296
272 477
430
303
250 350
600
250
272
531
172
428
401
332
250
296
302
346
531
371
401
265
401
590
276
265
592
346
275
320
276
592
320
70
250
426
577
33211
691
691
530
172
413
276
466
430
272
346
280
280
243
535
592
112
70
614
401
250
350
112
296
250
11
592
332 280
371
346
413
466
426
296
414
401
531 691
480
577
715
346
480
363
535
401
531
363
70
426
320
346
704
300
691
414
250
340
340
243
243
401
458
535
535
332
174
265
371
332
531
430
413
340
600 365
522530
704
522
276
577
401
531
345
70530
350350
592628
691
466
300
300
522
410
413
242
276
332
414
243
265
426
345
477 346
11
172
428
70
592
288
346
530
288
430
401
320
401
272
112
531
332
428
275
276
340303
615
275
530
112
477
480
530
480
458
530
628
696
535
458
413
704
530
696
174
320
493
466
614
535
413
522
371
430
242
320
112
477
363
346
696
11240
600
332
444
174
522
590
242
345
250
531
628
11
577
275
614
345
361477
696
410
371
303
243
200
243
371
295
715
444
174
710
614
414
363
240
174
696
272
345
426
592
691
70
320
295
628
200
577
162
704
288
522
250
363
466
345
531
276
276
426
477
174
174
174
320
535
200
295
172
275
363
371
371
332288
696
628
363
70
300
340
242
295
458
288
535
112
592
477
70
288
444
401
522
428
530
363
345
243
11
162
275
200
531
11
696
715
250
345
303
401
332
242
200
477
413
350
112
302
444
288
535
250
340
250
426
300
240
531
280
614
615
70
530
240
401
371
691
340
696
112
444
302361 361
530
458
615
345
200
710
444 600
174
276
426
444
715
332
340
200
428
480
710
340
302240
530
243
275
250
345
70
150
628
303
592
11
715
530
691
710
70
295
530
345
522
200
200
592
332
710
704
493
592
430
535
590
345
704
295
112
592
480
493
426
363
592
11
288
371
493
240
242
150
480
242
200
426
428
426
112
480
350
628
320
275
493
340
162
346
288
691
332
615614
458
275
276
112
172
428
522
275
410
70
295
303
428
466
179
320
710
530
401
628
361
346 240
691
11
614
628
303
696
480
477
11
280
531
363
320
243
628
350
577
691
242
466
615
493
288
242
150
150
628
332
590
288
288
200
715
150
295
350
361 361 361
200
361
70
428
530
426
70
480
444
691
710
295
628
288
320
250
530
590
615
361
162
295
275
320
288
303
710
350
112
615
458
430
458
300
70
477
296
296
280
332
715
444
614
295
522
200
696
363
150
162
480480
444600
592
401
296
466
200
410
410
696
112
414
174
477
288
522
413
458
715
715
172
590
345
444
240
174
172
172
530
150
150
112
350
240
288
458
410
172
590
458
428
242
240
444
371
162
704
275
535
150
477
320
303
365
243
350
288
288
296
350 11600
600
444
710
458
70
200
179
179
275
530
493
345
522
715
614
493
590
628
590
615
704
112
522
715
162
346
522
410
414
428
276
480
242
112
295
300
179
522
614
430
179
710
200
243
428
150
710
444
112
70
590
174
346
614
162
493
410
295
162
577
240350 361
288
150
428
179
592
466
615
296
444
628
493
493
275
172
493
426
480
303
371
162
715
361
340
340
242
615
172
363
710
112
365
240
295
614
162
162
426
200
493
265
493
493
303
428
480
300
477628
522
174
590
615
340
179
466
200
458
150
345
345
696
715
430
535
493
242
200
242
522
615
531
363
174
691
458
428
240
300
600
11
590
350
275
410
615
531
179
179
704
696
428
458
150
243
302 11
179
710
276
410
179
691
265
200
361
242
303
243
345
240
466
179
414
242
410
179
179
428
288
345
715
70
371
600 600 600
477
361
150
346
444
410
493
428
615
590
303
371
112
361361 302600
691
162
162
614
162
458
242242
590
590
710
590
477
361
280
477
493
715
615
590
704
332
350
296
340
295
172
280
410
295
410
265
691
696
300
361
240
300
240
11
480
150
365
426
361
150
179
614
288
174
162
162
361
240
300
340
466
250
493
466
179
458
288
361
162
715
428
363
162
710
522
179
272
162
112
150
426
179
493
480
365
590
704
696
302
346
346
480
11
704
303
371
240
172
179
531
444
200
332
150
295
590
710
276
577
280
530
275
715
303
401
615
296
300
240
150
320
577
350
332
410
240
303
600
361
477
704
704
426
162
615
179
704
628
11 11
112
704
174
179
458
615
242
332
179
265
243
410
150
531
710
691
350
477 302
615
150
614
150
162
275
414
535
243
458
363
615
428
371
590
600
715
275
615
150
401
243
174
614
172
320
162
162
614
70
691
300
361
480
710
174
150
172
530
410
243
477
280
590
628
477
340
410
242
172
615
172
275
303
150
430
410
174
577
715
363
295
320
480
628
715
172
428
410
172
410
174
296
600
346
600
401
535
466
493
320
428
150
179
691
710
715
174
710
350
444
444
174
179
414
430
275
365
350
615345
280
590
614
426
275
410
361
600
112
280
493
303
172
704
410
410
280
691
363
628
413
302
590
577
477
410
172
303
600
350
302240
243
174
710
535
458
428
401
365
280
112
11
710
276
172
428
179
150
615
172
413
240
240
614
428
320
704
710
300
600
590
162
11
288
715
280
466
361
340
365
300
413
172
242
704
414
458
361
240
240
444
600
628
696
345
493
70
365
615
280
522
600
162
444
715
615
577
275
590
530
345
590
704
162
242
710
276
414
276
280
280
530
410
340
280
276
172
466
704
345
350 11 240
444
243
458
172
615
480
240
240 350
350600361
480340
428
535
345
413
172
466
428
174
288
350
346
615
179
577
628
276
477
590
174
371
600 350 361
302
303
345
715
276
242
174
265
280
162
265
401
243
530
413
242
320
531
365
628
350
300
477
480
628
162
401
174
345
696
70
365
363
280
413
365
590
628
276
530
493
275
361
480
150
172
320
493
430
265
340
615
410
704
715
704
361
592480
444
363
410
466
715
696
458
590
710
350
340
428
363
426
493
600
302
300 592
150
480 240
302
530
340
70
715
150
444
242
710
715
413
577
250
275
696
466
691
276
340
303
11
480 365 480
11
363
332
240
614
531
696
11
628
242
200
493
162
577
250
250
458
577
288
350
300
592
413
426
265
413
243
535
401
577
522
365
243
577
628
280
371
243
276
577
696
710
250
426
320
704
458
691
296
592
704
696
590
361
480
346628
535
275
280
280
691
174
592 332
413
162
70
458
522
11
444
430
531
600
592
303
466
340
365
531
345
280
350
150
276
426
172
535
296296
477
444
243
413
493
280
371
363
200
243
696
300
276
458
300
303
600
200
346
414
696
715
691
112
296
628
710
426
276
112
272
340
200
265
531
691
6332
91
600
242
320
696
466
276
302
444
320
426
275
371
295
401
577
265
590
295
426
577
70
522
535
363
704
265
302 302
303303477
303
295
320
265
466
696
172
265
332
531
174
296
242
276
614
243
477
296
11 11
296
365
70
371
530
295
280
70
444
280
300
361
363
696
615
112
345 295
413
272
466
577
363
600
365
628
276
426
350
11
363
535
365
275
363
302 346 345
592
70
276
346
430
614
426
577
200
200
11
275
577
458
365
265
240
346444428
577
265
276
340
302
295
430
265
302 272
710
413
320
577
112
296592
426
628
458
200
365
696522288
250
426
430
275
430
466
430
320
577
691
242
11
295
458
365
592296
70
365
288
350
444
242
320
466
371
70
296
272272
112
295
531
477
592
345
250
426
466
493
614
288
413
265
371
200
300
365
243
265
414
535
691
522 480
363
466
265
345
535
265
200
614
480
302
477
303
295
401
272 112
614 174
430
365
477
250303
413
70
535
371
430
614
592112
346
346696
70
345
592
243
320
535
401
428
320
414
531
302112592
296
2
96
302
522
691
401
414
365
295
430 371
401
340
614 332
531
371
477
414
272
250
332
363
414
371 174691
592
371 413
430
332
265
340
530
428340 414
414
302
401 243
332
414
288 531
401
272
530
414
302
413
296
413
401
296
522
332
346
272 346
414
250
272
530
430 288 332
272 272
531
250
272
272
272
346
531
530

302
302

302

302
302

302

11

-1

250250

-.5

0
.5
Technological Opportunity Residual
Residuals

Fitted values

50

1

Table 1
Induced Pharmaceutical Innovation

Dependent variable:

ln

MitT OT AL

(1)

(2)

(3)

(4)

^ it )
ln(K

^ it )
ln(K

^ it )
ln(K

^ it )
ln(K

3:03
[1:31]
pwild = 0:002

ln MitAGIN G

ln

MitOBESIT Y

Fixed e¤ects
Number of observations

1:32
[0:70]
pwild = 0:042
3:25
[1:149]
pwild = 0:008

2:28
[1:38]
pwild = 0:111

2:84
[1:43]
pwild = 0:017

0:92
[0:77]
pwild = 0:188

Disease,
Class Year

Disease,
Class Year

Disease,
Year

Disease,
Year

3883

3883

3883

3883

Our statistical inference is based on pwild which is calculated using the cluster-robust standard error (clustered at the class level)
and the wild cluster bootstrapped distribution of the t-statistic (1000 iterations). Monte Carlo evidence favors this approach when the
number of clusters is small and the clusters are unbalanced (Cameron et al., 2007). The wild cluster bootstrapped standard error (1000
iterations) is presented in brackets.

51

Table 2
Determinants of All Medical Research

Dependent variable:

(1)

(2)

(3)

(4)

(5)

(6)

ln(NitALL )

ln(NitALL )

ln(NitALL )

ln(NitALL )

ln(NitALL )

ln(NitALL )

0:32
[0:16]
pwild = 0:027

0:22
[0:15]
pwild = 0:137

0:29
[0:14]
pwild = 0:014

0:22
[0:15]
pwild = 0:149

^ it
ln K

ln

MitAGIN G

2:74
[1:43]
pwild = 0:037

2:40
[1:29]
pwild = 0:083

1:76
[1:16]
pwild = 0:125

1:84
[1:18]
pwild = 0:168

2:66
[1:47]
pwild = 0:062

2:76
[1:28]
pwild = 0:023

ln

MitOBESIT Y

0:43
[1:18]
pwild = 0:773

0:004
[0:71]
pwild = 0:996

0:25
[0:98]
pwild = 0:800

0:13
[0:68]
pwild = 0:858

0:07
[1:05]
pwild = 0:947

0:13
[0:68]
pwild = 0:857

Disease,
Class Year

Disease,
Year

Disease,
Class Year

Disease,
Year

Disease,
Class Year

Disease,
Year

3884

3884

3883

3883

3796

3796

Fixed e¤ects
Number of observations

In columns 5 and 6 children’s mental health diseases (299, 314, 315) are omitted. See the footnote to Table 1 for an explanation of
the standard errors and p-values.

52

Table 3
Determinants of Drug-Related Medical Research
(1)

(2)

(3)

(4)

(5)

(6)

Dependent variable:

ln(NitDRU G 1 )

ln(NitDRU G 1 )

ln(NitDRU G 2 )

ln(NitDRU G 2 )

ln(NitDRU G 3 )

ln(NitDRU G 3 )

^ it
ln K

0:64
[0:36]
pwild = 0:021

0:58
[0:31]
pwild = 0:037

0:59
[0:30]
pwild = 0:022

0:48
[0:28]
pwild = 0:057

0:85
[0:35]
pwild = 0:006

0:74
[0:31]
pwild = 0:010

ln

MitAGIN G

2:51
[1:81]
pwild = 0:200

2:32
[1:09]
pwild = 0:008

2:46
[1:17]
pwild = 0:185

2:73
[1:22]
pwild = 0:015

3:85
[1:92]
pwild = 0:030

4:06
[1:93]
pwild = 0:019

ln

MitOBESIT Y

1:75
[2:02]
pwild = 0:525

1:79
[1:29]
pwild = 0:163

1:77
[1:91]
pwild = 0:489

1:57
[1:15]
pwild = 0:223

2:08
[2:11]
pwild = 0:451

1:87
[1:49]
pwild = 0:208

Disease,
Class Year

Disease,
Year

Disease,
Class Year

Disease,
Year

Disease,
Class Year

Disease,
Year

3730

3730

3730

3730

3697

3697

Fixed e¤ects
Number of observations

Children’s mental health diseases (299, 314, 315) are omitted. See the footnote to Table 1 for an explanation of the standard errors
and p-values.

53

Table 4
Determinants of Other Medical Research
(1)

(2)

(3)

(4)

(5)

(6)

Dependent variable:

ln(NitOT HER 1 )

ln(NitOT HER 1 )

ln(NitOT HER 2 )

ln(NitOT HER 2 )

ln(NitOT HER 3 )

ln(NitOT HER 3 )

^ it
ln K

0:20
[0:12]
pwild = 0:086

0:15
[0:13]
pwild = 0:339

0:06
[0:09]
pwild = 0:566

0:007
[0:09]
pwild = 0:950

0:11
[0:18]
pwild = 0:507

0:06
[0:16]
pwild = 0:726

ln

MitAGIN G

2:84
[1:53]
pwild = 0:056

2:82
[1:35]
pwild = 0:018

2:98
[1:57]
pwild = 0:062

2:79
[1:36]
pwild = 0:025

1:64
[1:24]
pwild = 0:181

2:59
[1:55]
pwild = 0:114

ln

MitOBESIT Y

0:23
[0:92]
pwild = 0:798

0:11
[0:52]
pwild = 0:830

0:13
[0:89]
pwild = 0:897

0:19
[0:69]
pwild = 0:787

0:51
[1:20]
pwild = 0:684

1:49
[0:81]
pwild = 0:066

Disease,
Class Year

Disease,
Year

Disease,
Class Year

Disease,
Year

Disease,
Class Year

Disease,
Year

3796

3796

3796

3796

3723

3723

Fixed e¤ects
Number of observations

Children’s mental health diseases (299, 314, 315) are omitted. See the footnote to Table 1 for an explanation of the standard errors
and p-values.

54

Table 5
Determinants of Type of Medical of Research
(1)
DRU G
Nit
ALL
Nit

(2)
3

DRU G
Nit
ALL
Nit

3

)

ln(

OT HER
Nit
ALL
Nit

3

0:53
[0:21]
pwild = 0:005

0:54
[0:21]
pwild = 0:001

0:25
[0:14]
pwild = 0:043

0:20
[0:12]
pwild = 0:089

ln MitAGIN G

0:79
[1:06]
pwild = 0:494

1:58
[1:05]
pwild = 0:196

0:62
[1:04]
pwild = 0:563

0:77
[0:92]
pwild = 0:459

1:69
[1:28]
pwild = 0:242

1:76
[1:07]
pwild = 0:105

0:65
[0:46]
pwild = 0:248

0:89
[0:48]
pwild = 0:073

Disease,
Class Year

Disease,
Year

Disease,
Class Year

Disease,
Year

3697

3697

3723

3723

Number of observations

ln(

3

^ it
ln K

Fixed e¤ects

)

OT HER
Nit
ALL
Nit

ln(

ln

ln(

(4)

Dependent variable:

MitOBESIT Y

)

(3)

)

Children’s mental health diseases (299, 314, 315) are omitted. See the footnote to Table 1 for an explanation of the standard errors
and p-values.

55

